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ABSTRACT 
Neuronal ceroid lipofuscinoses (NCLs) are a family of inherited pediatric 
neurodegenerative disorders, with an incidence of 1:12 500 in the US and 
Scandinavian countries and 1:100 000 worldwide. The major hallmarks of NCLs 
include retinal degeneration, death of selective neuronal populations and 
accumulation of autofluorscent ceroid-lipopigments. The clinical manifestations are 
generally similar in all forms. 
The Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCLFin) is a 
form of NCL, especially enriched in the Finnish population. The clinical symptoms 
include motor clumsiness, progressive retinal degeneration, motor and mental 
deterioration, myoclonia and seizures. 
The first aim of this thesis was to analyse the brain pathology of vLINCLFin utilising 
the novel Cln5-/- mouse model. The Cln5-/- mouse presented with the classical 
hallmarks of the vLINCLFin pathology, including autofluorescence and typical 
ultrastructure of the storage deposits in brains of the affected mice and therefore, 
proved to be an excellent model to study vLINCLFin. Gene expression profiling of 
the brains of already symptomatic Cln5-/- mice revealed that inflammation, 
neurodegeneration and defects in myelinization are the major characteristics of the 
later stages of the disease. 
Histological characterization of the brain pathology confirmed that the 
thalamocortical system is affected in Cln5-/- mice, being consistent with the 
findings from other NCL mouse models. Whereas the brain pathology in all other 
analyzed NCL mice initiate in the thalamus and spread only months later to the 
cortex, we observed that the sequence of events is uniquely reversed in Cln5-/- 
mice; the neurodegeneration begins in the cortex and becomes evident in the 
thalamus only months later. We could also show that even though 
neurodegeneration is inititated in the cortex, reactive gliosis and loss of myelin are 
evident in specific nuclei of the thalamus already in the 1 month old brain.   
To obtain a deeper insight into the disturbed metabolic pathways early in the course 
of the disease, we performed gene expression profiling of the mouse brains. We 
substantiated these findings with immunohistological analyses, and could 
  
demonstrate that cytoskeleton and myelin were affected in Cln5-/- mice. 
Comparison of gene expression profiling of two NCL mouse models further 
highlighted that the Cln5-/- and Cln1-/- mice share a common defective pathway, 
leading to disturbances in the neuronal growth cone and cytoskeleton.  
Encouraged by the first evidence of common pathogenetic mechanisms behind two 
forms of NCL, we systematically analyzed the molecular interactions of NCL-
proteins and observed that Cln5 and Cln1/Ppt1 proteins interact with each other. 
Furthermore, we demonstrated that Cln5 and Cln1/Ppt1 share an interaction partner, 
the F1-ATP synthase, potentially linking both LINCLFIN and INCL diseases to 
disturbed lipid metabolism. In addition, Cln5 was also shown to interact with other 
NCL proteins; Cln2, Cln3, Cln6 and Cln8 implicating a central role for Cln5 in the 
NCL pathophysiology. 
This study is the first to describe the brain pathology and gene expression changes in 
the Cln5-/- mouse. Together the findings presented in this thesis represent novel 
information of the disease processes and the molecular mechanisms behind 
vLINCLFin and have highlighted that the relatively rare Finnish CLN5/vLINCLFin 
forms a very important model to analyze the pathophysiology of NCL diseases, 
protein interactome and effects between genes and proteins leading to 
neurodegeneration in general. 
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ABBREVIATIONS 
AIF  apoptosis-inducing factor 
ANCL   adult neuronal ceroid lipofuscinosis (CLN4) 
apoA-I   apolipoprotein A-I 
BBB  blood brain barrier 
Cap-1  adenylate cyclase-associated protein 1 
cb  cerebellum 
cc   corpus callosum 
Ccl21a  chemokine (C-C motif) ligand 21 a gene 
CLN5/Cln5   CLN5 gene/protein 
CNP  2´,3´-cyclic nucleotide 3´-phosphodiesterase gene 
CNS   central nervous system 
CONCL  congenital neuronal ceroid lipofuscinosis (CLN10) 
COS-1 cells   African green monkey kidney cells 
CTSD  Cathepsin D gene 
Ddx6  DEAD (Asp-Glu-Ala-Asp) box polypeptide 6  gene 
DNA   deoxyribonucleic acid 
Drpla  dentatorubral-pallidoluysian atrophy protein 
EEG   electroencephalography 
EPMR Progressive epilepsy with mental retardation (CLN8) 
ER   endoplasmic reticulum 
ERG  electroretinogram 
ERGIC  ER and the ER-Golgi intermediate compartment 
ES  Embryonic stemcells 
GDNF  glial cell line-derived neurotrophic factor gene 
GFAP  glial fibrillary acid protein 
GO  Gene Ontology 
Gprc5b G-protein-coupled receptor family C, group 5, member B 
gene 
GROD  granular osmiophilic deposit 
HeLa cells   human cervical tumour cells 
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HIV  Human immunodeficiency virus 
IF  immunofluorescence 
IGFR  insulin-like growth factor receptor gene 
INCL  infantile neuronal ceroid lipofuscinosis (CLN1) 
JNCL   juvenile neuronal ceroid lipofuscinosis (CLN3) 
kDa   kilodalton(s) 
KH  K homology 
Kif5c  kinesin family member 5C gene 
Lent  late entorhinal cortex of thalamus 
LFB  luxol fast blue stain 
LGNd  dorsal lateral geniculate nucleus of thalamus 
LINCL late infantile neuronal ceroid lipofuscinosis (CLN2) 
LSD  lysosomal storage disease 
M1  primary motor cortex 
M6-P  mannose 6-phosphate 
MAG  myelin-associated glycoprotein  
MEG  magnetoencephaography 
MBP  myelin basic protein 
MFS  major facilitator superfamily 
MGN  medial geniculate nucleus of thalamus 
MHC  major histocompatibility complex 
Mnd  motor neuron degeneration 
MOG  myelin-oligodendrocyte glycoprotein 
MPR  mannose 6-phosphate receptor 
mRNA   messenger RNA 
MT  microtubule 
NCL  Neuronal ceroid lipofuscinosis 
NGF  nerve growth factor  
NMD  Nonsense-mediated decay 
NO  nitric oxide 
PAGE   polyacrylamide gel electrophoresis 
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PCD  Programmed cell death 
PCR   polymerase chain reaction 
PLP  proteolipid protein 
PLTP  plasma phospholipid protein 
PPT1/Ppt1  palmitoyl protein thioesterase 1 protein (CLN1) 
Ptprf  protein tyrosine phosphatate receptor type F gene 
Qk  quaking gene 
RNA   ribonucleic acid 
S1BF  somatosensory barrelfield cortex 
SAP, Saposin  sphingolipid activating protein 
SDS   sodium dodecyl sulphate 
SPF  pathogen free facilities 
STAR  signal transduction and activator of RNA 
TGN  trans-Golgi network 
Tia 1 cytotoxic granule-associated RNA binding protein 1 
TLC famliy  Tram-Lag1p-CLN8 family of genes 
tLINCL Turkish variant form of late infantile neuronal ceroid 
lipofuscinosis 
TNF-a  tumor necrosis factor alpha gene 
TNFR1  tumour necrosis factor receptor 1 gene 
TPP1  tripeptidyl peptidase I gene 
UPR  unfolded protein response 
V1  primary visual cortex 
vLINCL  variant form of late infantile neuronal ceroid lipofuscinosis 
(CLN6) 
vLINCLFin  Finnish variant form of late infantile neuronal ceroid 
lipofuscinosis (CLN5) 
VPM/VPL  ventral posterior thalamic nucleus 
WB  western blot 
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Xist  inactive X specific transcripts gene   
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1 INTRODUCTION 
Neurodegenerative disorders are a group of central nervous system disorders 
characterized by progressive death of brain cells. They comprise a large and 
increasing share of the global burden of disease. The World Health Organisation 
(WHO) has reported that although neurological diseases and mental illnesses are 
responsible for about 1% of deaths, they account for 11% of the disease burden 
(Oliver et al., 2005). 
Lysosomal storage disorders (LSDs) are a group of hereditary metabolic diseases, 
caused by defects in lysosomal proteins, or proteins affecting the function of 
lysosomes. The majority of lysosomal storage disorders lead to neurodegeneration 
and are therefore classified as neurodegenerative disorders. Neuronal ceroid 
lipofuscinoses (NCLs) are a group of lysosomal storage disorders, mostly affecting 
children. They are characterized by accumulation of lipopigments in the cells of the 
body and by progressive death of neurons. The NCLs are grouped according to the 
age of onset into 10 different subtypes. Yet all lead to death, usually within the 
second decade of life. 
The Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCLFin) is, 
although rare, especially enriched in the Finnish population. The disease manifests 
around the age of 4-7 years, with motor clumsiness and loss of vision being the first 
of many symptoms. 
A great deal of progress has been made in the vLINCLFin research during the past 
decade. However, the brain is a difficult organ to study and therefore much of the 
research has been based on brain material from already deceased patients. Results 
gained from these studies are able to shed light on disease processes at the end 
stages of the disease. However, to understand the initial patophysiology of the 
disease and to be able to develop therapies, it is crucial to study the disease process 
already at presymptomatic stages.  
The use of mouse models allows researchers to investigate diseases in ways that 
would not be possible in human patients. They are invaluable for studying 
pathophysiology and also for testing new approaches to therapy.   In this thesis, the 
aim was to investigate the brain pathology of vLINCLFin utilising the novel Cln5-/- 
mouse model. 
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2 REVIEW OF THE LITERATURE 
2.1 The mouse as a disease model 
Diseases are generally caused by defective cellular proteins and one essential goal of 
biological science is to resolve their physiological function. This is an overwhelming 
task, since every protein functions together with several others in the living cell. One 
approach is to use in vitro systems, such as cell cultures, to remove the protein of 
interest in order to study the consequences. However, a protein may have different 
functions in different cell types. Therefore, studying processes only in specific cell 
types in a controlled environment outside of a living organism, can lead to results 
which do not correspond to the situation that arises in a living organism.  
Revealing the physiological function of defective disease causing protein and 
characterizing their pathological events can enable the development of therapies for 
disease. There are however, many ethical issues concerning procedures 
performed on humans. As a result animal models have been generated to allow 
researchers to investigate disease states in ways which would be inaccessible in a 
human patient.    
Genetically altered mouse models can be used to study physiological functions of 
particular proteins as well as to model human diseases. Such mouse models have 
been used in the fields of immunology and developmental biology with great 
success for two decades now. These mouse models can be studied in numerous 
ways, ranging from biochemistry to cell biology, systems biology and behaviour. 
Within the past decade, the use of mouse-models to study diseases of the central 
nervous system has increased rapidly (Picciotto & Wickman, 1998).   
Genetically altered mouse models can be created in several ways. Transgenic mice 
are created by the addition of an extra gene in the mouse genome. This method is 
mostly used for models of dominantly inherited diseases, as the inserted mutated 
gene gives rise to a phenotype regardless of the two endogenous copies of the gene. 
Knock-out mice are produced by removing or altering DNA sequences in order to 
destroy a functioning gene in the mouse genome. This technique is used mostly 
when studying recessive diseases. Knock-out mice are generated by modifying a 
DNA sequence, which is then inserted into a cloned copy of the selected gene, by 
standard recombinant DNA technology. After that, the modification is transferred, 
by homologous recombination, to the related genomic locus in embryonic stem cells 
(ES cells). The ES cell lines carrying the desired mutation are then selected and 
injected into mouse blastocysts. The blastocysts are transferred into foster mothers, 
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generating chimeric mice that are able of transmitting the modified genetic locus to 
their offspring (Capecchi, 2001; Capecchi 1989). Knock-in mice can be used to 
investigate specific disease mutations. In this case the gene is neither overexpressed 
nor completely deleted. Manipulation of the endogenous gene can be achieved so as 
to mimic specific mutations occurring in human disorders. This allows the analysis 
of how the actual mutated protein product functions in the cell and contributes to the 
disease phenotype. If a gene is essential for the development, then destroying its 
function can lead to lethality during embryonic stages or at birth. In such cases, 
conditional mutant mice can be generated. Here the expression of the mutated gene 
can be regulated, by expressing or deleting them at different times of development 
or in different tissues (Hafezparast et al., 2002; Picciotto & Wickman, 1998).  
2.1.1 Benefits of mice 
As mammals, mice and humans are alike in many ways; sharing a large number of 
genes and biochemical pathways. Both humans and mice have approximately 
20,000 genes (Carninci & Hayashizaki 2007) and it has been estimated that 99% of 
human genes have counterparts in the mouse genome (Tecott, 2003). We 
furthermore have the same diseases as well as common anatomical features. Further, 
analysis of the behaviour of the mouse, including its social and emotional activity 
enables modelling of even complex neurological and psychiatric disorders (Oliver & 
Davies, 2005). 
There are many experiments that can be performed in mice which would not be 
possible to perform in humans, due to ethical concerns. In the case of 
neurodegenerative diseases, only tissues from the end stage of the disease are 
generally available from human subjects. However, early stage tissues can be 
obtained from mice allowing for the study of early symptomotology that manifest 
before neurodegeneration. Further, the mouse embryo can be studied to elucidate 
congenital or perinatal diseases. Additionally, new therapies, including gene 
therapies can be tested in mice before trials can be concidered in humans 
(Hafezparast et al., 2002; Oliver & Davies, 2005). 
Mice are common model animals because of their availability, size, low cost, ease of 
handling, and fast reproduction rate. They have a short gestation period, an early 
puberty and a short oestrus cycle. They usually produce large litters, and their 
mating as well as their environment can be strictly controlled (Willis-Owen & Flint, 
2006).  
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2.1.2 Potential pitfalls 
Strain. Multiple strains of inbred mice have been generated and maintained. The 
profound effects on mouse strains when creating a transgenic mouse must be taken 
into consideration. Knocking-out the same gene in two different mouse strains can 
lead to different phenotypes, since unlinked genes in the background strain can 
significantly affect the disease phenotype. The different mouse strains differ in, for 
example, their performance in the Morris water maze test, and in their visual and 
auditory abilities (Picciotto & Wickman, 1998).   
Differences in the life-span. Certain human disorders with late onset, may be 
difficult to model in mice. For example, in the case of some lysosomal storage 
diseases, a disease process might take years to develop in humans. It is possible that 
the same process does not have time to develop within the mere two years of a 
mouse lifespan. However, this is still debated, and the alternative opinion claims that 
a human lifespan equals a mouse lifespan, regardless the difference in years. The 
importance of the absolute timescale may be good to keep in mind (Suzuki et al., 
2003a).  
Compensatory genes. Some gene knockout mouse models do not show any 
obvious phenotypes. It is possible that the absence of a given gene is compensated 
for by other gene(s) (Thyagarajan et al., 2003). A well known example for this is the 
Hexa knock-out mouse, which was designed to model Tay-Sachs disease. Yet the 
mouse proved to have no neurological symtoms, due to the fact that there is a 
significant difference in the GM2 ganglioside metabolism between mice and humans 
(Taniike et al., 1995; Sango et al., 1995). 
Developmental state of birth. Mice and humans are not equally developed at birth. 
Using the brain as an example, human neuronal proliferation already occurs before 
birth. In mice this proliferation of neurons occurs postnatally, about 7-8 days after 
birth. The same differences apply to the active period of myelination, which occurs 
in mice approximately 20-25 days after birth, but takes place in the human brain 
right after birth. This is important when considering certain therapies. If a treatment 
is effective in a mouse only when given before the age of 10 days, then the same 
treatment should be administered to humans already in utero, in order to be effective 
(Suzuki et al., 2003a). 
Environment. Mouse models for diseases are usually maintained in pathogen free 
facilities (SPF). This raises an interesting question as to whether a disease phenotype 
is dramatically affected by pathogens in non-infectious diseases, such as recessively 
inherited lysosomal storage diseases.  
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2.2 Lysosomes and lysosomal storage disorders 
 2.2.1 Lysosomes and lysosomal proteins 
Lysosomes were discovered in 1955 by Christian de Duve, although the first 
lysosomal storage disease (LSD), Tay-Sachs’s disease, was already described in 
1881. De Duve and colleagues described lysosomes as a “new group of particles 
with lytic properties”. Today we know that lysosomes are membrane-bound 
organelles with an acidic pH, containing vesicles with hydrolytic enzymes (Vellodi, 
2005). 
Lysosomes are primarily the “break-down stations” of the cell as it is in them that 
substrate breakdown occurs. Macromolecules that have to be degraded are delivered 
to the lysosomes by endocytosis, autophagy, and phagocytosis or by direct transport 
across the lysosomal membrane (Sleat et al., 2005). Lysosomes additionally have 
functions in, downregulation of surface receptors, release of endocytosed nutrients, 
inactivation of pathogenic organisms, repair of the plasma membrane and loading of 
processed antigens onto MHC class II molecules (Mullins & Bonifacino, 2001). 
There are 50-60 hydrolytic enzymes and associated proteins contained within the 
lysosomes (Journet et al., 2002). They can degrade most macromolecules such as 
proteins, carbohydrates, lipids, and nucleic acids (Beck, 2007). The majority of the 
lysosome’s enzymes are localized to the luminal compartment and are generally 
soluble glycoproteins. Products resulting from hydrolysis are subsequently 
translocated from the intralysosomal compartment across the membrane and released 
into the cytoplasm for reuse (Bagshaw et al., 2005). 
Proteomic analyses have shown that lysosomes contain up to 215 integral 
membrane proteins, with different functions (Bagshaw et al., 2005). They maintain 
the acidic environment of the lysosome lumen, transport amino acids, fatty acids, 
carbohydrates and nutrients from the lysosome to the cytosol for reutilization and 
mediate fusion with other organelles (Beck, 2007; Eskelinen et al., 2003) 
Lysosomal enzymes are synthetized in the endoplastic reticulum (ER) where
they undergo several different modifications, such as removal of their signal
sequence and N-glycosylation. From the ER they are further transported to
the Golgi apparatus where a mannose-6-phosphate (M6-P) tag is attached to their
sugars for targeting transport to the lysosomes (Kornfeld & Mellman, 1989)
(Fig 1). However this step is not required for all lysosomal enzymes. Beta-
glucocerebrosidase, a lysosomal membrane associated protein, does not require 
the M6-P ligand, but is instead targeted to the lysosomes by LIMP-2 (Reczek et al., 
2007). Whilst some lysosomal enzymes, like Cathepsin D (Glickman & Kornfeld, 
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1993), sphingolipid activator proteins (SAPs) (Lefrancoiset al., 2003) and acid 
sphingomyelinase (Ni & Morales, 2007) use the sortillin receptor as an alternative 
route to the lysosomes. 
From the trans-Golgi network (TGN) the M6-P receptor-protein complex moves on 
to late endosomes, where the M6-P receptor is cleaved. The lysosomal enzyme is 
then transported to the lysosomes, while the receptor is recycled back to the TGN. In 
the lysosomes the proteins may undergo further protein modifications, such as 
proteolysis, folding and oligomerization (Vellodi, 2005).  
Lysosomal membrane proteins are not modified with M6P groups and therefore do 
not depend on the MPR for sorting. The targeting of lysosomal transmembrane 
proteins is instead mediated by short, linear sequences of amino acids, within the 
cytoplasmic domains of the proteins (Bonifacino & Traub, 2003). These signals 
include dileucine-based and tyrosine-based motifs and interact with clathrin coat 
components, to be transported to the lysosomes. The targeting of the lysosomal 
membrane proteins can additionally be regulated by lipid modifications, as has been 
shown for both Cln3 and mucolipin-1 proteins (Braulke & Bonifacino, 2008). 
Defects in any of the lysosomal proteins, in their targeting, activation and in their 
biogenesis, can all lead to lysosomal storage disease. 
 
2.2.2 Lysosomal storage disorders 
Today over 50 lysosomal storage diseases (LSDs) are known. They are 
characterized by intra-lysosomal accumulation of ungraded metabolites. LSDs are 
predominatly monogenic and resessively inherited, only Hunter’s disease, Fabry’s 
disease and Danon disease are not ingherited in this manner. LSDs have a tendency 
to be multisystemic and progressive. LSDs are due to defects in the breakdown of 
almost all types of molecules except for nucleic acids. Therefore, LSDs include 
lipidoses, mucopolysaccharidoses, oligosaccharidoses, and disorders of protein 
catabolism (Tardy et al., 2004). Several mutations in the same gene have been 
described for most of the LSDs. In some diseases the phenotypic variability can be 
explained by residual enzyme activity, however, no obvious genotype-phenotype 
correlations have been recognized. Patients with a similar genetic background or 
with the same disease mutation can present totally different phenotypes (Futerman & 
van Meer, 2004).  
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LSDs can be caused by (i) the deficiency of a given lysosomal hydrolase (the 
majority of LSDs), (ii) the deficiency of a protein that either activates or stabilizes 
one or several lysosomal hydrolases (as in GM2-activator deficiency, prosaposin 
deficiency, or galactosialidosis), (iii) the deficiency of an enzyme that participates in 
a) processing (e.g., as in mucosulfatidosis) b) targeting (as in mucolipidoses type II 
and III) of lysosomal enzymes and (iv) by defects of the lysosomal membrane
(Beck, 2007; Tardy et al., 2004)(Fig 1). 
LSDs can predominantly be divided into infantile, juvenile and adult forms. The 
infantile forms are the most severe, display brain pathology and result in death 
within the first years of life. The adult forms are much milder with slowly 
developing symptoms that usually attack the peripheral organs, rather than the brain. 
Juvenile forms are intermediate between the severe infantile and the milder adult 
forms. 
The symptoms of LSDs can be divided into neurological and peripheral. Around 
two-thirds of patients with LSDs develop neurological symptoms, which include 
seizures, dementia and brainstem dysfunction. Peripheral symptoms include 
hepatosplenomegaly, injury to the heart and kidneys, abnormal bone formation, 
muscle atrophy and blindness (Futerman & van Meer, 2004). LSDs are all 
characterized by their intra-lysosomal accumulation of unmetabolized substrates, 
which are likely to be the primary cause of the disease. However, the cellular 
pathways which lead to the variety of symptoms, and cause severe tissue damage, 
remain largely elusive. Remarkably, adult neurodegenerative disorders such as 
Alzheimer, Parkinson and Huntington diseases share many of the secondary events 
leading to pathology in the LSDs. Neurodegeneration, inflammation and 
hypomyelination are often associated with brain pathology in LSDs, and are thus 
discussed more thoroughly in the following chapter of the thesis. 
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Figure 1. Cellular basis of Lysosomal storage diseases. ss.= signal sequence 
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2.2.3  Neuropathology of LSDs 
LSDs are typified by production of an abnormal enzyme or other proteins of the 
endosomal lysosomal pathway, leading to accumulation of abnormally degraded or 
structurally aberrant molecules. The production of the abnormal enzyme/protein is 
the primary event that initiates a cascade of secondary events leading to pathology. 
In the central nervous system (CNS), these secondary elements include alterations in 
programmed cell death (PCD), as well as brain inflammation and demyelinization. 
These events lead eventually to neurodegeneration and affect the patients’ cognition 
and behaviour. Neuronal loss, in LSDs, usually occurs at advanced stages of the 
disease. Many of these fetures occur also in adult neurodegenerative disorders. Thus, 
the improved knowledge of the events behind neurodegeneration can benefit not 
only children suffering from LSDs, but also adult patients suffering from more 
complex type of neurodegeneration. 
2.2.3.1 Alterations in programmed cell death 
Programmed cell death (PCD) plays a critical role in neural development and in 
normal physiological processes of the cell. When something goes awry, and the 
regulation of one or several pathways of PCD is disturbed, it can lead to 
neurodegeneration and disorders of the nervous system. 
PCD is a complex phenomenon involving multiple pathways. It can be divided into 
at least three categories; apoptosis, autophagic cell death and necrosis (Bredesen, et 
al., 2006). The type of cell death selected depends on the stimulus and the cellular 
context because every cell death program is a net result of self-propagating signals 
and variable factors that suppress the other cell death programs. Moreover, the 
different PCD mechanisms can operate in parallel or sequentially with each other, 
with multiple switchpoints between them (Boujrad et al., 2007) and different death 
mechanisms may operate in different parts of the same stressed neuron at the same 
time. 
Apoptosis is a critical mechanism regulating neuronal cell number and proper 
connectivity in the developing nervous system. This makes it crucial for regulating 
brain development. Hallmarks of apoptosis have been observed both during 
neuronal development and neuronal cell death caused by acute and chronic injury 
(Yuan & Yankner, 2000). Apoptosis is characterised by distinct morphological 
features. They include cell shrinkage, chromatin condensation, blebbing of 
cytoplasmic membranes, and the fragmentation of cell bodies and nuclei into small 
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pieces that are called apoptotic bodies (Saraste, 1999). These apoptotic bodies are 
then phagosytosed by nearby macrophages or epithelial cells.  
Apoptosis can be activated through three distinct pathways; the extrinsic and two 
intrinsic pathways. The extrinsic pathway originates from the cell surface through 
Fas receptors and tumour necrosis factor receptor 1(TNFR1). The major intrinsic 
pathway, or the mitochondrial pathway, originates from mitochondria and the less 
well known second intrinsic pathway originates from the endoplasmic reticulum 
(ER).  The activation of the extrinsic pathway activates caspases 8 and 10 while both 
intrinsic pathways activate caspase 9. Caspases are proteolytic enzymes that cleave 
their substrates after specific aspartic acid residues. The extrinsic pathway is 
especially activated in pathological conditions in which inflammation is a prominent 
feature. The mitochondrial pathway is activated by stimuli such as heat, osmotic 
shock, DNA damage or growth factor starvation (Tardy et al., 2006). While stress in 
the ER, including the disruption of calcium homeostasis and accumulation of 
unfolded proteins in the ER (unfolded protein response, UPR), activate the second 
intrinsic pathway (Bredesen et al., 2006; Vila et al., 2003). Loss of control of 
apoptosis likely contributes to either degenerative (in case of too much cell death) or 
malignant (in case of too little cell death) diseases (Tardy et al., 2004). 
Apoptotic cell death has been implicated as a cell death mechanism behind the 
pathology of common diseases like Alzheimer’s and Huntington’s disease (Ribe et 
al., 2008; Gil & Rego 2008). Impairment of lysosomal function may affect apoptosis 
in many ways and apoptosis has been detected in several LSDs, including several 
forms of NCLs. Accumulation of a toxic compound due to deficient degradation, 
lack of a molecule acting as an apoptosis suppressor, absence of proteolytic 
processing of a protein involved in apoptosis and abnormal apoptosis signalling due 
to perturbations in intracellular trafficking, are all possible mechanisms leading to 
neurodegeneration through apoptosis (Tardy et al., 2004). Among NCLs, there is 
evidence of apoptosis in mouse models for Cln1, Cln3 and Cathepsin D deficiency 
(Gupta et al., 2001; Cotman et al., 2002; Koike et al., 2003; Seigel et al., 2002). In 
fact all of the above proteins; PPT1 (Cho, et al., 2000a; Cho & Dawson, 2000; 
Dawson et al., 2002), Cln3 (Puranam et al., 1999; Rylova et al., 2002;Persaud-Sawin 
et al., 2002) and Cathepsin D (reviewed in (Minarowska et al., 2007))  have 
themselves been implicated as playing a role in the regulation of apoptosis. 
Autophagy is an evolutionarily conserved and strictly regulated lysosomal 
degradation pathway for cytoplasmic material and organelles. It maintains cellular 
turnower, and it is characterized by two-membrane autophagic vacuoles in the 
cytoplasm. It is induced under pathological conditions, such as amino acid 
starvation, hypoxia or intracellular accumulation of damaged organelles and 
cytoplasmic components. Its role is perceived to be the maintaince of free amino 
acids for use in various cellular functions. Depending on the delivery route, 
autophagy can be divided in macroautophagy, microautophagy, and chaperone-
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mediated autophagy. Targets for degradation can for example be damaged 
mitochondria or misfolded protein aggregates. All autophagic vacuoles eventually 
fuse with lysosomes, which provide hydrolases as degrading enzymes (Klionsky & 
Emr., 2000; Bredesen, et al., 2006; Eskelinen & Saftig, 2008). In addition to its 
primary role in intracellular degradation, autophagy has also recently been shown to 
play an important role as an alternative cellular death mechanism. It has been 
reported to function in proliferation, death and differentiation during embryogenesis 
and postnatal development (Cecconi & Levine 2008).  
In addition to the important housekeeping and quality control functions that 
contribute to health, autophagy has also been connected to the pathogenesis of 
several human diseases (Eskelinen & Saftig 2008), most likely due to errors in the 
regulation of it. It has been shown that knocking-out autophagy proteins in mice 
causes neurodegeneration and accumulation of ubiquitin positive protein aggregates 
(Hara et al., 2006; Komatsu et al., 2006). Furthermore, enhanced autophagy has 
been shown to reduce the toxicity of the protein aggregates in Huntington’s disease, 
probably by preventing the formation of such aggregates (Ravikumar et al., 2004; 
Klionsky 2006). Defects in authophagy have also been implicated in several 
lysosomal storage diseases (LSDs). Most LSDs are caused by deficiencies of 
lysosomal hydrolases and therefore from accumulation of undegraded material in 
lysosomes. In these cases the authophagy-lysosomal fusion, and consequently 
degradation, is impaired, leading to neurodegeneraton. Such a mechanism has for 
example, been observed in mucopolysaccharidosis type IIIA (Settembre et al., 
2008). 
Increased autophagy has also been shown to be harmful. For example, in Nieman-
Pick type C disease an increased autophagic process is considered to be the reason 
for death of Purkinje neurons (Ko et al., 2005). Autophagy is considered to be 
involved in the pathogenesis of NCL diseases, as is the case for the Cathepsin D-/- 
mouse (Koike et al., 2005). Autophagy has, furthermore, been shown to be activated 
in Cln3 mice (ex7/8) with the development of autophagic vacuoles being 
disrupted in these mice (Cao et al., 2006). 
Necrosis is a form of PCD that includes swelling of the ER and mitochondria, and 
lacks typical apoptotic features such as apoptotic bodies and nuclear fragmentation 
(Bredesen et al., 2006). Necrosis was previously considered to be a passive form of 
cell death, but it has become clear that necrosis is controlled and can be activated by 
various stimuli, and certain developmental neuronal cell death has been found to 
exhibit features of necrosis. Necrosis has been shown to contribute to ovulation, 
immune defence, death of chondrocytes controlling the longitudinal growth of bones 
and cellular turnover in the intestine. Necrosis can lead to local inflammation, 
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presumably through the liberation of factors from dead cells that alert the innate 
immune system (Festjens et al., 2006). 
Necrosis has also been connected with several neurodegenerative diseases, such as 
Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, and amyotrophic 
lateral sclerosis. Although the molecular mechanisms of necrosis are not fully 
elucidated, it is thought that necrosis of adult neurons is mediated by increase of 
intracellular Ca2+, mainly due to ER stress reactions, and that cytosolic calpains and 
spilled lysosomal cathepsins are the major players in necrotic neuronal death 
(reviewed in Artal-Sanz & Tavernrakis 2005). Very little is however, known about 
necrosis in LSDs. Necrosis has been suggested as a cell death mechanism in 
Niemann-Pick C disease (Erickson & Bernard 2002), but there are no reports to 
date, of necrosis in any of the NCLs. 
Several pathological mechanisms exist that contribute to neurodegenerative diseases 
both in addition to/ or ultimately leading to PCD. These mechanisms can either act 
alone or in combination with each other. Suggested mechanisms include genetic 
factors, oxidative stress, excitotoxicity, protein aggregation, and damage to critical 
cellular processes, including axonal transport and organelles such as mitochondria 
(Shaw, 2005; Gil & Rego, 2008).  
2.2.3.2 inflammation 
The knowledge of the role of inflammation in the pathogenesis of neurodegenerative 
disease has increased rapidly in recent years. Neuroinflammation was previously 
considered to occur when damaged neurons induce an activation response from glia. 
Recent evidence, though, shows that glial cells (astrocytes, microglia, and 
oligodendrocytes) have “normal” housekeeping functions in the brain, which include 
transient upregulating of inflammation processes that are meant to be 
neuroprotective. These “normal” glial functions can then sometimes result in a more 
severe and chronic neuroinflammatory cycle that actually promotes 
neurodegenerative disease. Several possibilities exist for the relationship between 
inflammation and neurodegeneration: (1) that inflammation induces 
neurodegeneration; (2) that neurodegeneration causes inflammation; (3) other 
factors contribute to the development of inflammation and/or neurodegeneration; (4) 
inflammation and neurodegeneration participate in a cycle or a cascade in which 
they augment one another; and (5) that inflammation can protect against 
neurodegeneration. (Peterson & Fujinami, 2007) 
Astrocytes. Astrocytes are the most abundant cells in the CNS, with the ratio of 
astrocytes to neurons appearing to rise with the increased complexity in the CNS. 
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Until relatively recently, astrocytes were believed to be structural cells, with a sole 
function of holding neurons together. It is currently known however, that astrocytes 
have several other functions. These functions include: amino acid-, nutrient-, and ion 
metabolism in the brain, coupling of neuronal activity and cerebral blood flow, and 
modulation of excitatory synaptic transmission (Maragakis & Rothstein, 2006).  
Astrocytes are known to release gliotransmitters, such as glutamate and D-serine. By 
releasing these gliotransmitters, in a process called gliotransmission, they can 
control neuronal synaptic activity. It has been suggested that defects in 
gliotransmission, either hyper- or hypoactivity, could contribute to disorders of the 
nervous system, such as epilepsy or schizophrenia (Halassa et al., 2007). 
In response to CNS pathology, such as neurotrauma, brain ischemia, or 
neurodegenerative diseases, astrocytes can become reactive and migrate to the site 
of injury. This is known as reactive gliosis or astrocytosis. Reactive gliosis is 
characterized by a distinctive change in the appearance of astrocyte, called 
hypertrophy and by the proliferation of microglial cells and astrocytes. The best 
known hallmark for reactive gliosis is the upregulation of intermediate filament 
proteins, especially glial fibrillary acid protein (GFAP), but also vimentin and nestin 
(Pekny & Nilsson, 2005). This group of responses result in the formation of a tightly 
compacted limiting glial margin termed the astrogliotic scar, which is known to 
inhibit neurite outgrowth. These ‘reactive’ astrocytes may also aggravate tissue 
damage by releasing proinflammatory cytokines, such as tumor necrosis factor  
(TNF-a), which can inhibit neurite outgrowth and kill oligodendrocytes. They can 
release, for example, nitric oxide (NO) and reactive oxygen species that can 
adversely affect cell survival after injury (reviewed in (Carmen et al., 2007; Liberto 
et al., 2004)) 
Although reactive gliosis has been considered the major obstacle to axonal 
regeneration, recent data suggest that in certain conditions, reactive astrocytes can 
actually support neurons. It has been shown that reactive astrocytes can metabolize 
the stored glycogen and in this way support neighboring neurons, by exporting 
glucose or lactate to them. Astrocytes can, furthermore, minimize damage and 
neuronal death by regulating harmful glutamate levels caused by excitotoxic 
neuronal death.  They also mediate repair by secreting neurotrophic factors, such as 
nerve growth factor (NGF), NT-3, and glial cell line-derived neurotrophic factor 
(GDNF) and are known to promote remyelinisation and regulate neurogenesis 
during development. Astrocytes maintain the blood brain barrier (BBB) and 
participate in reforming it following CNS injury. They also participate in the 
synaptic structure by enveloping the synapse, and are in this way able to maintain 
synapses after injury and promote synaptogenesis (reviewed in (Carmen et al., 2007; 
Liberto et al., 2004)). 
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Microglia are considered to be the resident macrophages of the CNS, sharing many 
similarities with cells of the monocyte lineage (Ling & Wong, 1993). Microglia can 
become activated in response to, for example, infectious agents, damaged cells or 
tissues, altered molecules, or neurotransmitter imbalance (Schwartz et al., 2006). 
They may also be stimulated by astrocytes (McGeer & McGeer, 2008). Once 
activated, microglia undergo a dramatic transformation from their resting ramified 
state into an amoeboid morphology, they proliferate, upregulate major 
histocompatibility complex (MHC) molecules and secrete cytokines, chemokines, 
nitric oxide and reactive oxygen species. These cytotoxic substances are secreted in 
order to destroy infected neurons, viruses, and bacteria, but microglia can become 
overactive and cause large amounts of collateral damage by this mechanism. This 
could result in large scale neural damage, as the microglia destroy the brain in an 
attempt to abolish invading infections. Additionally, activated microglia can also 
become phagocytic, engulfing the offending material, such as bacteria, apoptotic 
cells, or myelin debris (Peterson & Fujinami, 2007; Block et al., 2007). 
Traditionally it has been thought that the activated state of microglia can aggravate 
brain damage, and that decreasing microglial activation can be protective for the 
CNS. However, as is the case with astrocytes new data has emerged suggesting that 
microglia may also have neuroprotective functions. It would appear that the tilt 
toward harmful or beneficial outcomes is dependant upon the activating conditions 
(Hanisch & Kettenmann, 2007). It has been suggested that microglia may become 
dysfunctional as a result of aging, and would, therefore, be less equipped to sustain 
neuronal function. Microglia might also become dysfunctional from disease 
potentially aggravating the neurodegenerative process. Nonetheless, beneficial 
effects of microglia exist. Microglia are potentially promotors of migration, axonal 
growth, and terminal differentiation, of different neuronal subsets in the developing 
brain, conducted through the release of extracellular matrix components, soluble 
factors, and direct cell to cell contact (Vilhardt, 2005). In the adult CNS microglia 
are involved in processes such as tissue repair, neurotrophic support, induction of 
inflammation, or activation of lymphocytes. 
On the whole, inflammation in the CNS can be described as a series of local immune 
responses that are recruited to damaged tissue, with the outcome ultimately 
dependent on its regulation. Therefore, whether inflammation is good or bad for 
recovery of the damaged CNS apparently depends on how it is regulated. 
Consequently, even if the presence of activated glia is observed in almost any 
neurological disease, they might have to be regarded as mainly beneficial, becoming 
destructive only when they escape from the strict control normally imposed on them 
(Schwartz et al., 2006). 
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Two disease states where microglial pathology has been shown to play a prominent 
role include Human immunodeficiency virus (HIV)(Garden, 2002) and the Prion 
diseases (v Eitzen et al., 1998). Microglia are also known to be affected in some rare 
genetic brain diseases, like PLO-SL (Kiialainen et al., 2005). Microglial pathology 
has not widely been studied in LSDs, but to date, it is known that widespread 
astrocytic activation is a general feature in the later stages of human and animal 
NCLs (Haltia, 2003). However, regionally defined reactive gliosis has recently been 
shown to be present in Cln3 (Pontikis et al., 2005), Cln5 (see 5.2.3 in this thesis) and 
Cln6 (Oswald et al., 2005; Kay et al., 2006), long before any signs of 
neurodegeneration or clinical symptoms become evident.  
2.2.3.3 defective myelinisation 
Oligodendrocytes are mature glial cells that myelinate axons in the brain and spinal 
cord. Myelin, a key component of brain white matter is formed from an extended, 
modified oligodendrocyte plasma membrane surrouding a portion of an axon in a 
spiral fashion. An oligodendrocyte may wrap up to 40 axons.  Along one axon, 
neighboring myelin segments might belong to different oligodendrocytes (Baumann 
et al., 2001). 
The brain is still immature at birth, with most of the process of myelination occuring 
within the two first years of life. The myelin membrane is a lipid bilayer composed 
of cholesterol, phospholipids and glycolipids, interrupted by proteins. The two major 
myelin proteins are; myelin basic protein (MBP) and proteolipid protein (PLP), 
which together represent 80% to 90% of the total myelin protein. Other proteins 
include myelin-associated glycoprotein (MAG), myelin-oligodendrocyte 
glycoprotein (MOG), and 2´,3´-cyclic nucleotide 3´-phosphodiesterase (CNP). 
Myelination enables fast conduction along the axon, and loss of myelin decreases 
the conduction velocity and destabilizes the molecular structure of the axonal 
cytoskeleton. Myelin is distributed in small segments along the axon. In the small 
regions between the segments, the nodes of Ranvier, clusters of sodium channels 
enable the axon membrane to produce action potentials (Lyon et al. 2006; van der 
Knaap et al., 2001). Due to these important functions of myelin, oligodendrocytes 
have important functions in maintaining axon integrity and neuron survival as well 
as providing support for neuronal somas, by synthezising several neurotrophic 
factors (McTigue & Tripathi 2008). 
CNS white matter may be affected in different ways, with major differences in the 
underlying pathology. There can be a permanent myelin deficiency, the process of 
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myelination can be disturbed, the myelin sheath may be lost, myelin splitting may 
occur, extracellular oedema may involve CNS white matter, the white matter can be 
affected by gliosis, and lastly axonal damage can affect the myelin integrity. The 
situation is usually complex with the concurrence of several types of pathology (van 
der Knaap et al., 2001). White matter abnormalities are known to play a role in the 
pathogenesis of many neurological diseases in human. Several lysosomal storage 
disorders are included in this category. Diseases with myelin defects include; defects 
in genes encoding myelin proteins, peroxisomal diseases, mitochondrial diseases, 
disorders of amino acid and organic acid metabolism, defects of nuclear DNA 
repair, muscular dystrophies, macro/micro deletion syndromes, neurocutaneous 
syndromes and others (Lyon et al. 2006; van der Knaap et al., 2001). All white 
matter diseases share a similar set of clinical features. A period of normal 
development usually precedes the onset of neurological signs and symptoms. Then 
spasticity, motor weakness and ataxia develop, followed by optic atrophy and in 
some cases by seizures. Patients also suffer from behavioral and cognitive changes 
(Lyon et al. 2006). 
Many myelin mutant mouse models have been analysed to clarify the relationships 
between myelin-, axon-, lipid- and immunopathology. These models have revealed 
different genetic defects of myelin (Baumann et al., 2001). Jimpy and Shiverer are 
two examples of mouse models with white matter defects due to mutations in myelin 
structural proteins, PLP (Knapp et al., 1986; Duncan et al., 1989) and MBP (Roach 
et al., 1983; Wiktorowicz et al., 1991) respectively. The absences of either of these 
two proteins results in oligodendrocyte death and myelin breakdown. The CNS of 
the shiverer mouse is hypomyelinated, but the peripheral nervous system (PNS) 
appears normal. The myelin of the CNS, wherever present, is not well compacted 
and lacks the major dense line (Readhead & Hood 1990).  
Mutations involving enzymes of lipid metabolism can also induce myelin defects. 
The twitcher mouse, a model of Krabbe´s disease (belonging to the LSD disease 
group), suffers from mutations in the gene coding for galactosylceramidase 
(GALC)(Suzuki et al., 2003b). It is suggested that the accumulation of psychosine, a 
toxic metabolite, which is also a substrate for GALC, leads to apoptotic death of 
oligodendrocytes and subsequent demyelination (Jatana et al., 2002). Other 
mechanisms may also be involved in the processes of demyelination, and include; 
inflammation, oxidative stress, neurotransmitters (especially glutamate), heat shock 
proteins and matrix metalloproteinases (Baumann, et al., 2001). Loss of myelin is 
observed in several forms of NCLs (A. Haapanen, submitted). However, the 
mechanism(s) leading to these myelin defects are still unknown. 
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2.3 NCL diseases 
Neuronal ceroid lipofuscinoses (NCLs) are a family of inherited pediatric 
neurodegenerative disorders, with an incidence of 1:12 500 in the Nordic countries 
and in the U.S.A. Elsewhere in the world the incidence is approximately ten times 
lower (Santavuori, 1988). NCLs are classified as lysosomal storage disorders 
(LSDs) since they present accumulation of membrane-bound intracellular protein 
aggregates (Futerman & van Meer, 2004; Kyttala et al., 2006), and are caused by 
mutations in endosomal-lysosomal proteins or proteins of the endoplasmic reticulum 
(ER) (Weimer et al. 2002). However, contrary to most other LSDs the storage 
material in NCLs is not a disease specific substrate (Elleder et al., 1993). 
The NCLs were initially categorized into four different groups, based on age of 
onset; infantile form (INCL, age of onset 6-24 months, CLN1), late- infantile form 
(LINCL, age of onset 2-8 years, CLN2), juvenile form (JNCL, age of onset 4-10 
years, CLN3) and adult form (ANCL, age of onset 11-50 years, CLN4). Later 
many different variants were discovered, which did not fit into the original 
categories, due to delayed age of onset or less severe, or protracted symptoms (Table 
1)(Mole et al., 2005). 
NCLs are autosomally recessively inherited, with the exception of some rare 
dominant adult forms (Peltonen et al., 2000). Currently, it is known that NCL can be 
caused by approximately 160 mutations in 8 known NCL-genes, CLN1, CLN2, 
CLN3, CLN5, CLN6, CLN7, CLN8 and CLN10 (http://www.ucl.ac.uk/ncl/)(Siintola 
et al., 2006a; Siintola et al., 2006b; Siintola et al., 2007; Steinfeld et al., 2006). The 
molecular genetic basis for CLN4 and CLN9 are still unknown. It is probable 
however, that the number of NCL genes is larger, since mutations in another 
lysosomal protein CLCN7, cause osteopetrosis and an NCL-like disease in mice 
(Jentsch, 2008). Existing family material implicates that at least three more LINCL-
causing genes exist (A. Lehesjoki, unpublished). 
The major hallmarks for NCLs are the death of selective neuronal populations and 
the progressive accumulation of autofluorscent ceroid-lipopigments. The clinical 
manifestations are generally similar in all forms including; visual impairment caused 
by retinal degeneration and eventually leading to blindness, sleep problems, motor 
abnormalities, epilepsia, dementia and finally premature death (Haltia et al. 2006; 
Haltia et al. 2003; Williams et al., 2006). 
Although several of the gene defects for many of the NCL disorders have been 
known for many years, the pathology and the events leading to these disorders are 
still largely unknown. 
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Gene Disease Congenital Infantile Late Infantile Juvenile Adult 
CLN1 INCL   O O O O 
CLN2 LINCL   O O     
CLN3 JNCL      O     
CLN4 ANCL         O 
CLN5 vLINCLFin     O O    
CLN6 vLINCL     O     
CLN7 tLINCL     O     
CLN8 EPMR/NE     O O   
CLN9 vJNCL       O   
CLN10 CONCL O   O     
 
Table 1. Ages of onset for different forms of NCL 
2.3.1 Congenital and Infantile NCLs 
2.3.1.1 Congenital NCL/ CLN10 
The congenital neuronal ceroid lipofuscinosis (CONCL) is the earliest and most 
aggressive form of NCLs. This disorder is very rare and only a few cases have been 
described. The patients suffer from microcephaly, respiratory problems, rigidity and 
epileptic attacks, dying within hours to weeks after birth. A massive loss of cortical 
neurons as well as extensive gliosis and absence of myelin can be seen in the brains 
of the patients (Steinfeld et al., 2006). Autofluorescent storage bodies, typical for 
NCLs, with a granular osmiophilic deposit (GROD) ultrastructure are observed in 
the patient cells. The GRODs reside in the lysosomes and resemble autofluorescent 
lipofuscin pigments that accumulate in cells during normal aging. However, GRODs 
rarely contain lipid droplets, which differentiates them from normal aging pigments 
(Lu,et al. 1996; Tyynelä, et al. 1993). GRODs have a packed globular structure 
which is more granular and tightly packed in neurons and coarser and looser in non-
neuronal cells. GRODs can be detected for diagnostic purposes in blood 
lymphocytes and skin dermal cell types (Mole, et al. 2005). The major storage 
material in CONCL consists of sphingolipid activator protein D (Saposin D). 
However, the storage material seems to vary between species, accumulation of 
saposins A and D (similarly to INCL) can be observed in humans and sheep 
THL — Research 6 30 Animal model and Molecular 
interactions of Cln5
2 Review of Literature
  
(Tyynela et al., 2000) while subunit c of the mitochondrial ATPase (similarly to 
other NCLs, except for INCL) is found in mice (Koike et al., 2000). 
Mutations in Cathepsin D (CTSD), located on chromosome 11p15.5, (Faust et al., 
1985) were quite recently discovered to be the cause for this disease (Siintola et al., 
2006b; Steinfeld et al., 2006). CTSD is an aspartic protease that localizes to the 
lysosomes (Tang & Wong, 1987; Dittmer et al., 1999). Several in vitro substrates 
have been assigned to CTSD, including prosaposin (proSAP), which can be cleaved 
into saposins A and D (Gopalakrishnan et al., 2004), but no in vivo substrates are yet 
known. CTSD has, however, been implicated to function in processes related to cell 
proliferation, antigen processing, apoptosis, and regulation of plasma HDL-
cholesterol levels (Table 2)(Berchem et al., 2002; Moss et al., 2005; Haidar et al., 
2006; Benes et al.,2008). 
One patient with a mutation in CTSD is known to present a disease course 
resembling more variant late infantile forms of NCLs than CONCL (Steinfeld et al., 
2006; See 2.3.2.6 in this thesis). 
2.3.1.2 Infantile NCL /CLN1 
The infantile neuronal ceroid lipofuscinosis (INCL) will be discussed in chapter 
2.3.6. 
2.3.1.3 Other NCLs with infantile onset 
Some patients with mutations in the CLN2 gene (see 2.3.2.1), that usually manifest 
in a late infantile disease, are known to have an infantile onset disease (Ju et al., 
2002). 
2.3.2 Late infantile and variant NCLs 
2.3.2.1 Late infantile NCL/ CLN2 
The late infantile neuronal ceroid lipofuscinosis (LINCL) manifests in late infancy, 
between the ages of 2-4. The CLN2 gene deficient in the disease is located on 
chromosome 11p15 and codes for a pepstatin insensitive carboxyl protease called 
tripeptidyl peptidase I (TPP I) (Sleat et al., 1997). TPP I is a lysosomal serine-
carboxyl proteinase that removes tripeptides from the N-termini of polypeptides 
(Table 2.)(Sleat et al., 1997; Golabek & Kida, 2006). 56 mutations in the CLN2 gene 
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are known to date (http://www.ucl.ac.uk/ncl/), but no genotype-phenotype 
correlation has been reported. 
The ultrastructural feature of the storage material in LINCL patients is curvilinear 
profiles that aggregate in membrane-bound lysosomal residual bodies. The 
curvilinear body is a hallmark for LINCL mutations and it is a reliable diagnostic 
target. It can be observed in within the nervous system and extraneural tissues, 
including blood lymhocytes (Mole et al, 2005). The major storage component in 
LINCL is subunit c of the mitochondrial ATPase. Patients suffer from widespread 
neuronal loss in their brain, manifesting especially in the cerebellum and 
hippocampus (Palmer et al., 1992). 
No in vivo substrates are known for TPP I, but it is known that TPP I can cleave 
subunit c in vitro (Ezaki et al., 1999). TPP I reportedly interacts with two other NCL 
proteins, namely CLN3 and CLN5, based on coimmunoprecipitation and in vitro 
binding assays, but the relevance of these interactions and the in vivo function of 
TPP I itself remains elusive (Vesa et al., 2002).  
In addition to classical LINCL, mutations in the CLN2 gene are also known to cause 
juvenile- (Hartikainen et al., 1999; Sleat et al., 1999; Steinfeld et al., 2002; 
Wisniewski et al., 1999) and infantile-forms (Ju et al., 2002) on NCL. 
2.3.2.2 The Finnish variant late infantile NCL / CLN5 
The Finnish variant form of late infantile neuronal ceroid lipofuscinosis 
(vLINCLFin) is a variant form of LINCL mostly affecting Finnish patients. 
vLINCLFin will be discussed in chapter 2.3.5. 
2.3.2.3 Variant late infantile NCL/ CLN6 
Variant late infantile neuronal ceroid lipofuscinosis (vLINCL), resembles 
phenotypically the classical LINCL, with a similar disease phenotype, apart from a 
later onset (3-8 years) and a slower progression (Mole et al., 2005). vLINCL results 
from mutations in the CLN6 gene,  positioned on chromosome 15q23 (Sharp et al., 
1997). Presently 27 disease mutations are known, with little variation in their 
disease phenotype (http://www.ucl.ac.uk/ncl/).  
The CLN6 gene codes for a transmembrane protein with 7 membrane-spanning 
domains. The CLN6 protein is localized in the endoplasmic reticulum (ER). No 
function has yet been assigned for CLN6, although the defect of this protein results 
in lysosomal dysfunction (Table 2) (Heine et al., 2004; Mole et al., 2004). Lamina V 
of the cortex is most severely affected by neuronal loss in vLINCL patients (Elleder 
et al., 1997). 
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As in other variant LINCLs, the major storage component in vLINCL is subunit c of 
the mitochondrial ATPase, and the ultrastructure of the storage material show 
fingerprint-, curvilinear- and rectilinear profiles (Elleder et al., 1997). Fingerprint 
profiles are membrane-bound, electron-dense bodies composed of paired parallel 
dark lines separated from each other by a lighter intervening layer of varying 
thickness. They may be mixed with curvilinear or rectilinear profiles even within the 
same storage cytosome (Haltia 2003). 
2.3.2.4 The Turkish variant late infantile NCL /CLN7 
The Turkish variant form of late infantile neuronal ceroid lipofuscinosis (tLINCL) is 
caused by a defect in the newest member of the NCL gene family, the MFSD8 gene 
located on chromosome 8q28.1-q28.2 (Siintola et al., 2007). The clinical course in 
tLINCL is similar to that of classical LINCL, apart from having more severe 
seizures. The age of onset ranges between 2 and 7 years of age (Mitchell et al., 
2001; Topcu et al., 2004). 
The ultrastructure of the storage material consists of fingerprint-, curvilinear- and/or 
rectilinear profiles and the major storage component is subunit c of the 
mitochondrial ATPase (Mitchell et al., 2001; Topcu et al., 2004). 
Six mutations have been identified in the MFSD8 gene (http://www.ucl.ac.uk/ncl/), 
which codes for a polytropic integral membrane protein with 12 transmembrane 
domains (Siintola et al., 2007). The lysosomal MFSD8 protein is suggested to be a 
member of the major facilitator superfamily (MFS), which is a large protein family 
of secondary active transporters. This family of proteins is known to carry small 
soluble compounds, such as sugars, drugs, inorganic as well as organic cations and 
many metabolites (Kasho et al. 2006). Neither substrate specificity nor functions of 
the MFSD8 protein are known (Table 2). 
2.3.2.5 variant late infantile NCL / CLN8 
The CLN8 gene, which is localized on chromosome 8p23, codes for the CLN8 
protein (Ranta et al., 1999; Lonka, et al. 2000). CLN8 is a membrane protein with, 
probably four-seven transmemrane domains. CLN8 is known to cycle between the 
ER and the ER-Golgi intermediate compartment (ERGIC) (Lonka, et al. 2000), and 
belongs to the Tram-Lag1p-CLN8 (TLC) protein family. Even though the function 
of CLN8 is unknown, TLC-proteins are known to participate in the biosynthesis, 
metabolism, transport and sensing of lipids (Table 2)(Winter & Ponting, 2002). 
Recently TLC-proteins have been linked to the regulation of acyl-CoA dependent 
ceramide synthesis (Riebeling et al., 2003). 
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Mutations in the CLN8 protein gives rise to two phenotypically different NCL 
disorders; Progressive epilepsy with mental retardation (EPMR) or Northern 
epilepsy and vLINCL (Ranta et al., 1999; Ranta et al., 2000; Cannelli et al., 2006; 
Zelnik et al., 2007). The more severe vLINCL is discussed here, but as Northern 
epilepsy is the mildest form of childhood NCLs it will be discussed with the other 
Juvenile NCLs in chapter 2.3.3.2.  
vLINCL patients were initially thought to suffer from tLINCL, before mutations in 
the CLN8 gene were discovered. Nonetheless, the clinical symptoms resemble those 
of the other variant LINCLs, with an age of onset between 2-7 years of age (Topcu 
et al., 2004). To date 11 mutations in the CLN8 gene are found to result in disease 
(http://www.ucl.ac.uk/ncl/). The storage material of the patients consists of subunit c 
of the mitochondrial ATPase and shows fingerprint- and/or curvilinear profiles as 
well as occasional GRODs (Topcu et al., 2004; Ranta et al., 2004; Cannelli et al., 
2006; Zelnik et al., 2007). 
2.3.2.6 Other NCLs with late infantile onset 
A small group of both CONCL (Steinfeld et al., 2006) and INCL (Das et al., 1998) 
patients, usually suffering from disorders of early infancy have disease courses that 
resemble that of LINCL. Additionally, existing family material of variant late 
infantile NCLs suggests that at least three more genes causing LINCL are still to be 
identified (A Lehesjoki, unpublished). 
2.3.3 Juvenile NCLs 
2.3.3.1 Juvenile NCL / CLN3 
The juvenile form of neuronal ceroid lipofuscinosis (JNCL) is also known as Batten 
disease and is globally the most common form of NCLs. The CLN3 gene defective 
for JNCL located on chromosome 16p12 encodes for a protein of the same name. 
The CLN3 protein is a hydrophobic integral membrane protein with, most likely, six 
transmembrane domains (Consortium. 1995; Kyttälä et al., 2004; Nugent et al., 
2008). CLN3 localizes predominantly to the lysosomes (Jarvela et al., 1998). The 
neuronal localisation differs slightly from extra neural cells, because CLN3 is 
additionally reported to localize to early endosomes and synaptosomes (Kyttala et al. 
2004; Storch et al., 2007; Luiro et al., 2001). Small amounts of CLN3 have also 
been shown to localize to the plasma membrane, in lipid rafts in neurons (Rakheja et 
al., 2004). More than 40 mutations in CLN3 are known to result in JNCL 
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(http://www.ucl.ac.uk/ncl/). Most of these result in juvenile onset disease, but 
atypical protracted or delayed disease forms are also known to exist. The genotype-
phenotype correlation is somewhat unclear, but recent evidence suggests that 
mutations in distinct domains of CLN3 result in different phenotypes, indicating 
several functional roles for CLN3 (Kitzmuller et al., 2008). 
The JNCL disease begins with visual failure, somewhat later than in the late 
infantile forms, between the ages of 4-10 years. In addition to the more typical NCL 
symptoms, JNCL patients also suffer from different psychiatric symptoms, such as 
aggressiveness, depression and sleep problems (Jarvela et al., 1997; Santavuori et 
al., 1993; Santavuori et al., 2000; Williams et al., 2006).  
As in most other NCLs, subunit c of the mitochondrial ATPase is the major storage 
material and the ultrastructure consists of fingerprint profiles (Carpenter et al., 
1977).  
Many different functions have been assigned to CLN3. It is thought to participate in 
the maintenance of lysosomal pH, in arginine transport and in the modification of 
proteolipids. It is also suggested to participate in some of the cell death mechanisms, 
in autophagy and in the prevention of apoptosis. CLN3 might also take part in 
cytoskeleton linked processes and in both vesicular transport as well as with 
membrane trafficking (Table 2) (reviewed by (Kyttala et al., 2006). Recent results 
have also linked CLN3 to fodrin-mediated endocytosis of Na+,K+,ATPase (Uusi-
Rauva et al., 2008). 
Related to the mentioned functions, CLN3 is reported to interact with Hook1, based 
on in-vitro binding (Luiro et al., 2004), Calsenilin, based on in-vitro binding and 
immunoprecipitation assays (Chang et al. 2007), Na+, K+ ATPase and Fodrin, based 
on yeast two-hybrid screening (Uusi-Rauva et al., 2008). Furthermore, CLN3 
interacts with two other NCL proteins, CLN2 and CLN5, based on 
coimmunoprecipitation and in vitro binding assays (Vesa et al., 2002). 
2.3.3.2 Northern epilepsy/ CLN8 
Northern epilepsy is the mildest form of childhood NCLs and manifests exclusively 
in Finnish patients. The age of onset is between 5-10 years of age and it is caused by 
mutations in the CLN8 gene (Ranta & Lehesjoki, 2000). Mutations in CLN8 are 
known to produce a more severe NCL, vLINCL, which is discussed in chapter 
2.3.2.5.  
All, but one, Finnish Northern epilepsy patients are homozygous for the same 
missense mutation (Ranta et al., 1999). The patients suffer from generalized tonic-
clonic seizures. In contrast to all other childhood NCLs, none of the patients suffer 
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from retinal degeneration (Ranta & Lehesjoki, 2000). Progressive cerebellar and 
brainstem atrophy is evident already in young adults (Lang et al., 1997). 
The storage material consists of subunit c of mitochondrial ATPase and the 
ultrastructure is curvilinear as well as granular (Hermansson et al., 2005). 
2.3.3.3 CLN9 
The CLN9 disease is the first of the two NCLs left with undiscovered gene defects. 
CLN9 resembles JNCL to a degree, but can be classified as its own entity based on 
the differing gene expression pattern and the phenotype of CLN9 patient cells. The 
characteristics for these fibroblasts include; rapid growth, sensitivity to apoptosis, 
defects in cell adhesion and reduced levels of ceramide, dihydroceramide as well as 
sphingomyelin (Schulz et al., 2004). 
As mentioned previously no gene defects have been found to date and all other 
known NCL genes have been excluded as candidates. Nevertheless, CLN8 has been 
shown to partially correct the phenotype of CLN9-/- cells (Guillas et al., 2001). 
Based on the data collected from CLN9 patient cells there has been suggestions that 
the CLN9 protein might function in regulating dihydroceramide synthase (Table 
2)(Schulz et al., 2006). 
The ultrastructure of the storage material comprises of GRODs, fingerprint and 
curvilinear profiles. Subunit c of the mitochondrial ATPase has been found in one 
patient (Schulz et al., 2004). 
2.3.3.4 Other NCLs with juvenile onset 
Mutations in the CLN1 gene, normally resulting in INCL, are known to sporadically 
cause a juvenile onset disease (Mitchison et al., 1998), whilst a mutation in the 
CLN5 gene, normally resulting in vLINCLFin is known to result in a juvenile onset 
disease in one Colombian family (Pineda-Trujillo et al., 2005). 
2.3.4 Adult NCLs 
2.3.4.1 Adult NCL or CLN4 
The second form of NCLs with a yet undiscovered gene defect, that has been given 
the genetic assignment CLN4, is the adult neuronal ceroid lipofuscinosis (ANCL). 
ANCL is the mildest form of NCLs with an age of onset ranging from 11 up to 50 
years of age (Berkovic et al. 1988). The gene defect is thought to be most likely 
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heterogeneous and other NCL genes are regarded as possible candidates. As an 
example, mutations in the CLN1 gene (INCL) can produce an adult-onset NCL (van 
Diggelen et al., 2001). 
Other features that support the hypothesis of a heterogeneous genetic background, 
include; the finding of the ultrastructure of the storage material which varies 
between GRODs, fingerprint, curvilinear and rectilinear profiles and the storage 
material containing both subunit c of the mitochondrial ATPase and Saposins A and 
D (Berkovic et al., 1988). 
In most cases ANCL is inherited in an autosomal recessive manner, and referred to 
as Kufs disease. However, in some cases the mode of inheritance is autosomal 
dominant and in these cases ANCL is referred to as Parry disease (Berkovic et al., 
1988). 
2.3.4.2 Other NCLs with adult onset 
Three adult cases have been described with mutations in the CLN1 gene, normally 
resulting in an infantile onset disease. The disease onset occurs in the third or fourth 
decade of life and the disease progress is slow (van Diggelen et al., 2001; 
Ramadanet al., 2007). 
 
Figure 2. The cellular 
localization of the known NCL 
proteins. CLN6 and CLN8 are 
localized in the endoplasmic 
reticulum (ER), whereas 
CLN1/PPT1, CLN2/TPP1, 
CLN3, CLN5, CLN7 and 
CLN10/Cathepsin D (CtsD) 
are localized in the lysosomes. 
CLN3, CLN6; CLN7 and 
CLN8 are transmembrane 
proteins, while CLN1,CLN2, 
CLN5 and CtsD are soluble. 
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2.3.5 CLN5 
2.3.5.1 Clinical features  
The Finnish variant late infantile neuronal ceroid lipofuscinosis (vLINCLFin) was 
originally described in Finnish patients. vLINCLFin, represents a typical example of 
a disease belonging to the Finnish disease inheritage (Santavuori, et al., 1982). 
vLINCLFin resembles the classical LINCL, apart from the later onset and slower 
course of the disease. The first symptoms of the disease appear usually between the 
ages of 4-7 years. They begin with attention deficits followed by motor clumsiness, 
learning problems and progressive visual failure, which eventually leads to 
blindness. Other typical symptoms include motor and mental detoriation, myoclonia, 
epileptic seizures and sleep disturbances. By the age of 10 years most patients are 
blind and they have lost both their ability to speak and to walk. vLINCLFin patients 
die usually around their second decade of life, although variations occurs between 
14-39 years (Santavuori et al., 1982; Santavuori et al., 1991). Mutations in CLN5 
can in some cases result also in a juvenile onset disease (Pineda-Trujillo et al., 
2005).  
The brain pathology of the patients reveals severe neuron loss both in the cortex and 
the cerebellum. The Purkinje and granular represent the major cell populations that 
are dying in the cerebellum (Santavuori et al., 1982), whereas neurons in laminae III 
and V are most vulnerable in the cortex (Tyynela et al., 1997). Reactive gliosis 
accompanies the neuron loss in the cortex (Santavuori et al., 1982). Progressive 
optical atrophy and loss of myelin add to the brain pathology of vLINCLFin patients 
(Autti et al., 1997).  
At the time of diagnosis, neuroimaging usually show generalized brain atrophy, with 
the cerebellum being predominantly affected. The periventricular white matter 
shows abnormally high signal intensity and the thalami show decreased signal 
intensity to the basal ganglia on T2-weighted images (Santavuori et al., 2000). 
Magnetoencephaography (MEG) of CLN5 patients has shown a selective 
enhancement of the early cortical response to median nerve stimulation (Lauronen et 
al., 2002). This may reflect defective interneuronal inhibition in the cortex. 
The ultrastructure of the storage material resembles that of the other late variant 
NCL’s, with rectilinear, curvilinear and fingerprint profiles. The main protein of the 
storage material is subunit c of the mitochondrial ATPase, although small amounts 
of Saposins A and D have also been found (Santavuori et al., 1982; Tyynela et al., 
1997) 
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2.3.5.2 The CLN5 gene and protein 
The CLN5 gene was originally localized to chromosome 13q22by Savukoski and 
colleagues (Savukoski et al., 1998). The gene contains four exons and translates into 
a 407 amino acid protein with a molecular mass of 38-60 kDa, depending on 
glycosylaton (Isosomppi et al., 2002). 13 mutations in the CLN5 gene have been 
found to result in vLINCLFin (http://www.ucl.ac.uk/ncl/). 94% of the Finnish patients 
carry the major mutation, the CLN5FinMajor, which results in a truncated protein, 
unable to be transported further than to the Golgi complex (Holmberg et al., 2000). 
The CLN5 gene is conserved in eukaryotes and the protein has no known 
homologues, which has made it rather difficult to predict any functions for the 
protein. Consequently, the function(s) of CLN5 has remained elusive. 
Human and mouse CLN5/Cln5 are widely expressed in all tissues.  Expression 
begins at an early developmental stage and increases during corticogenesis 
(Heinonen et al., 2000b; Holmberg et al., 2004). CLN5 is most likely to be a soluble 
lysosomal protein, with eight potential N-glycosylation sites. It is found in the M6-P 
proteome, suggesting that it is targeted to the lysosomes via the M6-P receptor 
pathway. Our recent results suggest, however, that CLN5/Cln5 might also utilize an 
alternative pathway, due to the fact that it is present in the lysosomes in M6-P 
receptor deficient cells (Schmiedt & Bessa, manuscript in preparation). Additional 
locations, apart from the lysosomes, have been suggested for the CLN5 protein in 
neurons. It has been reported to localize to the cell soma as well as to neural 
extensions (Holmberg et al., 2004). Yet, no functions related to lysosomes or these 
alternative locations have been assigned for CLN5 (Table 2).  
CLN5 interacts with CLN2 and CLN3, based on coimmunoprecipitation and in vitro 
binding assays (Vesa et al., 2002). These were the first interactions reported between 
any NCL proteins, and even though no functional relevance of these interactions has 
been found to date, it still implied, for the first time, that all NCL proteins could be 
connected. 
2.3.6 CLN1 
Infantile neuronal ceroid lipofuscinosis (INCL) is enriched in the Finnish population 
with an incidence of 1:20 000 (Santavuori et al., 2000). The INCL patients are 
symptom free at birth but start to manifest symptoms around 6 months of age. 
Delayed head growth (microcephaly) and muscular hypotonia are the only early 
signs of this devastating disease. The symptoms continue with visual failure, 
epileptic seizures, mental and motor deterioration, irritability and sleep problems. 
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Most patients have lost all their motor abilities and their vision by the age of three 
years. By this stage they have furthermore lost their social interest and suffer 
from increased spasticity, seizures and myoclonia. INCL patients usually die around 
10 years of age (Santavuori et al., 1973; Santavuori et al 1974; Santavuori et al., 
2000). Around 50% of all INCL patients suffer from this infantile form of NCL, but 
mutations in the CLN1 gene, can also result in late infantile (Das et al., 1998), 
juvenile (Mitchison et al., 1998) and even in some cases, adult onset variants of the 
disease (van Diggelen et al., 2001; Ramadan et al., 2007). It has been suggested that 
mutations near the active site of the protein result in an infantile form, whereas 
missense mutations in the peripheral parts of the protein result in later onset disease 
(Bellizzi et al., 2000; Das et al., 2001).   
The brain pathology of INCL patients implicates a progressive neuron loss, reactive 
gliosis and macrophage infiltration in the cortex. The cortical neurons are almost 
totally lost by the age of three years. At that time, magnetic resonance imaging 
shows extreme cerebral and cerebellar atrophy with very high signal intensity in the 
white matter. The electroencephalography (EEG) becomes flat and the 
electroretinogram (ERG) is extinguished (Santavuori et al., 1999). The brain atrophy 
is striking when the brain is autopsied, revealing almost complete loss of both 
cerebral and cerebellar cortices. Adding to the severe brain pathology, an almost 
complete loss of myelin and atsrogliosis can be seen throughout the whole brain 
(Haltia et al., 1973).  
INCL together with CONCL differ from the other NCLs concerning the 
ultrastructures of the storage materials, which comprise of GRODs. The major 
proteins in these inclusions have been determined to be saposins A and D (Tyynela 
et al., 1993) instead of subunit C, found in most other forms of NCL.  
2.3.6.1 The CLN1 gene and protein 
The gene defected in INCL is called CLN1. It was mapped to chromosome 1p32 by 
Vesa and colleagues in 1995 (Vesa et al., 1995). The gene consists of 9 exons and 
codes for a protein called Palmitoyl protein thioesterase or PPT1. 45 mutations in 
the CLN1 gene are known to date (http://www.ucl.ac.uk/ncl/). The PPT1 protein 
consists of 306 amino acids and migrates as a 37/35 kDa doublet. It contains three 
N-linked glycosylation sites, which are required for both the stability and acticity of 
the protein. PPT1 has been crystallized, and it resembles a classical /ß-serine 
hydrolase, a typical structure for lipases (Verkruyse & Hofmann, 1996; Bellizzi et 
al., 2000). PPT1 is expressed in most tissues and this expression is developmentally 
regulated. The expression of PPT1 appears to start early; the expression has been 
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detected as early as embryonic day 8 in mouse embryos (Isosomppi et al., 1999; 
Suopanki et al., 1999). 
PPT1 is a soluble lysosomal enzyme. It is M6-phosphorylated and consequently uses 
the M6-P route to lysosomes (Verkruyse & Hofmann, 1996; Hellsten et al., 1996). 
However, many other locations have also been assigned to PPT1 in neurons. These 
include the cell soma, axonal varicosities, presynaptic terminals and especially 
synaptosomes and synaptic vesicles. (Ahtiainen et al., 2003; Heinonen et al., 2000a; 
Isosomppi et al., 1999; Lehtovirta et al., 2001; Suopanki et al., 2002). Additionally, 
PPT1 has been reported in lipid raft preparations (Goswami et al., 2005).  The pH 
range for PPT1 activity is broad and unusually high for a lysosomal protein, which 
could imply functionality also outside of lysosomes. 
2.3.6.2 Functions of PPT1 
PPT1 is an enzyme that removes palmitate groups from other proteins. PPT1 is 
known to cleave palmitate from s-acylated proteins (Camp & Hofmann, 1993). It 
can depalmitoylate several proteins in vitro, such as H-Ras, Gap-43 and rhodopsin 
(Camp & Hofmann, 1993; Cho et al. 2000b). However, no in vivo substrates are 
known yet. Only another depalmitoylating enzyme is known apart from PPT1, acyl 
protein thioesterase or APT1 (Lu & Hofmann, 2006). Palmitoylation is a reversible 
protein modification that is attached to proteins post-translationally. Palmitoylation 
increases protein hydrophobicity, facilitates protein interactions with lipid bilayers, 
and can markedly alter protein sorting and function. It is known to modify numerous 
classes of neuronal proteins, including neurotransmitter receptors, synaptic 
scaffolding proteins and secreted signalling molecules (el-Husseini & Bredt, 2002). 
The exact physiological function of PPT1 is, however, not yet known. PPT1 has 
been proposed to participate in several different processes of the cell, such as 
apoptosis, endocytosis, vesicular trafficking, synaptic function and lipid metabolism 
(Table 2) (reviewed in (Jalanko & Braulke 2008). 
PPT deficient lymphoblasts are known to be sensitive for apoptosis and 
overexpression of PPT1 appears to protect against apoptosis (Cho & Dawson 2000). 
Conversly, other results show that reduced expression of PPT1 increases the 
susceptibility for induced apoptosis. PPT1 deficient fibroblasts show an elevation of 
lysosomal pH, which might imply defects in endocytosis. Recent data shows that 
PPT1 interacts with the ectopic F1-ATP-synthase, based on surface plasmon 
resonance and GST-pulldown assays, which can function as an ApoA1 receptor at 
the plasma membrane (Kim et al., 2004; Martinez et al., 2003; Moser et al., 2001). 
The complete functional consequence of this interaction is yet unknown, but 
functional data has revealed that the plasma phospholipid protein (PLTP), 
THL — Research 6 41 Animal model and Molecular 
interactions of Cln5
2 Review of Literature
  
cholesterol and ApoA-1 levels are significantly reduced in the sera of Ppt1-deficient 
mice, which suggest a role for PPT1 in cellular lipid metabolism (Lyly et al., 2008). 
 
 
Table 2. The functions and interaction partners of NCL proteins 
2.3.7 Mouse models of NCLs 
Mouse models have proved to be invaluable tools for dissecting the disease 
mechanisms in NCLs. Mouse models are available for all but one of the genetically 
characterized NCL subtypes (Table 3). tLINCL caused by mutations in the recently 
characterized MFSD8/CLN7 gene (Siintola et al., 2007) is not represented by a 
mouse model to date. All mouse models display phenotypes that resemble those of 
their respective human disorders (Table 3) (Cooper et al., 2006; Jalanko and Braulke 
et al., 2008). 
Gene  Protein  Function  Interaction partners  
CLN1  PPT1  
Cleaves palmitate from other proteins, in 
apoptosis, endocytosis, vesicular trafficking, 
synaptic function and lipid metabolism. 
 F1-ATP 
synthase  
CLN2  TPP1  A serine-carboxyl proteinase that removes tripeptides from the N-termini of proteins.  CLN3, CLN5  
CLN3  CLN3  
Functions in maintenance of lysosomal pH, 
arginine transport, modification of proteolipids, 
autophagy, prevention of apoptosis, 
cytoskeleton linked processes, vesicular 
transport,  membrane trafficking and 
endocytosis of Na+,K+,ATPase    
CLN2, CLN5, 
Hook1, 
Calsenilin, 
Na+, K+ 
ATPase, 
Fodrin  
CLN4  -  -  -  
CLN5  CLN5  -   CLN2, CLN3 
CLN6  CLN6  -  -  
CLN7   MFSD8  A suggested member of the major facilitator 
superfamily (MFS)   -  
CLN8  CLN8  Belongs to the Tram-Lag1p-CLN8 (TLC) protein family  -  
CLN9  -  Regulates the dihydroceramide synthase   -  
CLN10  Cathepsin D 
Functions in cell proliferation, antigen 
processing, apoptosis and regulation of plasma 
HDL-cholesterol levels  
-  
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2.3.7.1 Cln1 
Two mouse models for CLN1 have been produced by different targeting strategies; 
The Cln1-/- mouse made by Gupta and colleagues, has an insertion mutation in exon 
9 (Gupta et al., 2001) and the Ppt1ex4 mouse made by Jalanko and colleagues with a 
deletion in exon 4 (Jalanko et al., 2005). The mice display a severe phenotype, with 
a widespread inflammation-mediated neurodegeneration, resembling that of INCL, 
in the later stages of the disease.  
Localized reactive gliosis as well as neurodegeneration is evident in the Cln1 
deficient mouse-models. These events are predominantly localized to the thalamo-
cortical systems, with the earliest events described in the thalamus, especially 
thalamic relay nuclei of the visual system and later moving to the corresponding 
target neurons in the cortex, most likely as a consequence from the reduced 
signalling from the thalamus (Bible et al., 2004; Gupta et al., 2001; Kielar et al., 
2007 ).  
Gene expression studies in young Cln1-/- mice have revealed expression changes in 
immediate early genes, a group of genes that are defined as the first to be expressed 
following specific extracellular signals (Qiao et al., 2007). Inflammation related 
changes already dominate in 6 month old mice (Jalanko et al., 2005), whereas in 10 
week old presymptomatic Cln1-/- mouse brains, changes in single genes were 
reported with no specific pathways reported (Elshatory et al., 2003). Expression 
profiling made on cultured neurons derived from Ppt1ex4 mice revealed alterations 
in cholesterol metabolism, neuronal maturation and calcium homeostasis (Ahtiainen 
et al., 2007).   
Studies on the Cln1 deficient mice have revealed that the pool of readily releasable 
synaptic vesicles is diminished in Cln1-/- neurons (Virmani et al., 2005; Kim et al., 
2008). PPT1 deficiency is known to cause persistent membrane sorting and retention 
of several synaptic vesicle (SV) proteins which are known to undergo 
palmitoylation. This is likely to disrupt the recycling and regeneration of fresh 
vesicles, thus disrupting neurotransmission (Kim et al., 2008). However, data from 
neuron cultures and acute brain slices reveal no alterations in the synaptic 
transmission in Ppt1ex4mice (Ahtiainen et al., 2007). Furthermore, a deficiency 
linked to ER-mediated cellular stress leading to increased apoptosis is evident in 
Cln1-/- neurons (Kim et al., 2006). It has, however, later been shown by the same 
research group that ER stress leading to apoptosis is a common feature in many 
other lysosomal storage diseases, both neurodegenerative and non-
neurodegenerative, and would thus not be specific to INCL (Wei et al., 2008). In 
line with the previous results concerning localized reactive gliosis, the (receptor for 
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advanced glycation end-products) RAGE signaling pathway has also been shown to 
be activated in astroglial cells, mediating pro-inflammatory cytokine production and 
contributing to the inflammation process (Saha et al., 2008). 
In addition to the connection to defects in cholesterol metabolism by gene 
expression analysis, recent results (Ahtiainen et al. 2007; Lyly et al., 2008) 
demonstrate an increase in the cholesterol biosynthesis and a defective ApoAI 
metabolism in Ppt1 ex4 mice. 
2.3.7.2 CLN2 
The activity of TppI has been abolished to create the mouse model for CLN2 (Sleat 
et al., 2004). The mouse resembles LINCL with a rapid neurodegenerative 
phenotype. Pathological characterisations have revealed a pronounced degradation 
of the thalamo-cortical system, with first symptoms appearing in the thalamus, 
alongside cerebellar atrophy (Sleat et al., 2004). A progressive reactive gliosis is 
evident in the motor cortex, hippocampus, striatum and cerebellum (Chang et al., 
2008). 
2.3.7.3 CLN3 
JNCL is the most studied among NCLs with four different mouse models created to 
mimic the disease. The Cln3-/- mouse, which was generated by deleting exons 1-6 is 
the best characterised of them all (Mitchison et al., 1999). Other mice include 
Cln3ex7-8 (Cotman et al., 2002), Cln3 knock-out mouse (made by deleting exons 7-8 
as the previous mouse model)(Katz et al., 1999) and the Cln3 knock-in mouse, 
produced by deleting exons 1-8 with an extra ß-galactosidase reporter gene (Eliason 
et al., 2007). 
All of the mice replicate the cellular pathology of JNCL with subunit c of the 
mitochondrial ATPase and fingerprint profiles, but the mice scarcely show any 
visible symptoms (Cooper et al., 2006). 
Pathological analyses have demonstrated a selective loss of inhibitory interneurons 
(Mitchison et al., 1999). As in most other NCL-mice, the thalamo-cortical system is 
a target for neurodegeneration, beginning in the thalamus and preceeded by a low 
level of glial activation  (Pontikis et al., 2005; Pontikis et al., 2004). However, recent 
studies claim that there is no actual neurodegeneration in the Cln3 ex7-8 with the 
observed neuron loss suggested to be age related (Herrmann et al., 2008). 
Pathological changes have also been reported in the optical nerve (Weimer et al., 
2006). A specific unique feature for the Cln3 deficient mouse is the presence of 
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autoantibodies, similar to JNCL disease (Chattopadhyay et al., 2002; Castaneda & 
Pearce, 2008). 
Gene expression studies combined with molecular analyses have demonstrated 
changes in mitochondrial glucose metabolism, cytoskeleton, and synaptosome in the 
Cln3-/- mice (Luiro et al., 2006). 
Studies on neuronal cultures from Cln3-/- mice have revealed defects in the 
endocytic pathway and in the transport and processing of Cathepsin D (the protein 
defected in CONCL). The neurons also show disturbed mitochondrial morphology 
and slight functional disturbances (Fossale et al., 2004; Luiro et al., 2006) The mice 
further suffer from selectively increased vulnerability to AMPA-type excitatory 
glutamate receptor toxcicity (Kovacs et al,. 2006; Kovacs & Pearce, 2008). 
2.3.7.4 CLN6 
There exists a natural mouse model for vLINCL, the nclf-mouse. The 
neurodegenerative phenotype resembles that of human patients (Gao et al., 2002; 
Bronson et al., 1998; Wheeler et al., 2002), with myelination defects, 
neurodegeneration, neuromuscular defects and progressive retinal atrophy and 
gliosis. Results from lipid analyses show accumulation of gangliosides GM2 and 
GM3 (Jabs et al., 2008). 
2.3.7.5 CLN8 
The motor neuron degeneration (mnd) mouse is a naturally occurring mouse strain, 
modelling EPMR disease (Ranta et al., 1999). It has a progressive neurodegenerative 
phenotype, which resembles more the severe vLINCL disease than EPMR disease, 
with retinal degeneration and severe paralysis. However, no epileptic seizures are 
evident in the mnd mouse (Messer et al., 1993; Messer et al., 1995). Even though 
this is the case, the mouse still replicates the changes in lipid metabolism, seen in 
EPMR patients (Vance et al., 1997). Increased concentrations of oxiradicals and 
lipid peroxides have also been found in mnd mice (Bertamini et al., 2002; Guarneri 
et al., 2004).  
Some results have suggested that alterations in the glutamaergic neurotransmission 
may contribute to the disease in the mice (Battaglioli et al., 1993; Mennini et al., 
1998; Mennini et al., 2002). 
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2.3.7.6 CLN10 
The Cathepsin D (Ctsd) knock-out mouse is made by disruption of exon 4. The mouse 
presents a very grave phenotype, with the visceral organs affected in addition to the 
CNS (Saftig et al., 1995). The Ctsd-/- mouse only lives for 26 ±1days and it suffers 
from severe seizures. The seizures are connected to impaired GABAergic 
neurotransmission and reduce amount of GABA in the hippocampus (Shimizu et al., 
2005; Saftig et al., 1995). 
The pathological changes are pronounced in the thalamo-cortical system, and as in 
other NCL-models, starting in the thalamus and subsequently moving to the target 
neurons in the cortex. Reactive gliosis and microglial activation is also evident. 
Further pathological changes in the Ctsd-/- mouse include loss of neurons and 
synapses along with axonal degeneration (Partanen et al., 2008). 
Additional studies have revealed that autophagic stress within the cells is evident, 
appears early on and increases with age (Koike et al., 2000; Koike et al., 2003). 
Apoptotic cell death has also been suggested as a mechanism for neurodegeneration 
in Ctsd deficient mice (Koike et al., 2003; Minarowska et al., 2007). 
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  Human gene Mouse 
Onset of 
symptoms Phenotype Neuropathology Other characteristics 
C
O
N
C
L
 
Cathepsin D Ctsd-/- knockout 3 weeks 
Severe seizures, blindness, 
anorexia 
Thalamocortical atrophy, 
progressive gliosis, axonal 
degeneration 
Impaired GABAergic 
neurotransmission, accumulation of 
GM2 and GM3, abnormal 
lysophospholipid, apoptotic cell 
death 
CLN1 Pptex4 knockout 4 months 
I
N
C
L
 
CLN1 Ppt-/- knockout 2 months 
Loss of vision,  motor 
abnormalities,  seizures 
Thalamocortical atrophy, 
progressive gliosis 
Synaptic abnormalities, slight 
changes in Ca, early changes in 
neuronal cholesterol biosynthesis 
CLN2 
Tpp1 neoins 
Arg446His knock-out 
9 weeks 
Constant tremor, motor 
abnormalities, ataxia  
Thalamocortical atrophy, 
cerebellar atrophy, progressive 
gliosis 
n.d. 
CLN6 
Cln6nclf spontaneous 
mutant 
8 months 
Motor dysfunctions, spastic 
limb paresis 
  Retinal atrophy 
Accumulation of GM2 and GM3, 
reduced expression of GABAA2 
L
I
N
C
L
 
a
n
d
 
v
a
r
i
a
n
t
s
 
CLN8 
Cln8mnd spontaneous 
mutant 
4 months Severe paralysis   Retinal atrophy 
Changes in lipid metabolism, 
alterations in glutamatergic 
neurotransmission 
CLN3 Cln3-/- knock-out 16 months 
CLN3 Cln3ex7/8 knock-in 10-12 months 
CLN3 Cln3 knock-out 14 weeks 
n.d. 
Late-onset thalamocortical 
atrophy, early low level glial 
activation, optic nerve 
degeneration 
Vulnerability to glutamate receptor 
overactivation, mild mitochondrial, 
synaptic and cytoskeletal 
abnormalities, autoimmune 
response, autophagy 
J
N
C
L
 
CLN3 
Cln3 del ex1-8, ins -
gal 
2 months 
Motor dysfunctions, 
reduced nocturnal activity, 
tremors, increased 
sensitivity to PTZ-induced 
seizures  
n.d n.d. 
Table 3. NCL mouse models, adapted from (Cooper et al., 2006; Jalanko & Braulke, 2008). n.d. = not determined
TH
L —
 R
esearch 6
47
A
nim
al m
odel and M
olecula
r
 
interactions of Cln5
2 R
eview
 of Literature
  
3 AIMS OF THE STUDY 
Prior to this study, both the clinical features of vLINCLFin patients and the CLN5 
gene and disease causing mutations had been characterized. The CLN5 protein had 
been initially analysed but its function remained elusive. Consequently, the disease 
mechanism behind vLINCLFin was unknown. Similar pathological features had been 
discovered in many NCLs, but no knowledge existed about common disease 
mechanisms and only initial connections had been observed between the affected 
proteins. 
The aims addressed in this study were as follow: 
 
• To analyse the brain pathology of vLINCLFin utilising the novel Cln5-/- 
mouse model 
 
• To analyse changes in gene expression in the novel Cln5-/- mouse model 
 
• To discover possible common affected molecular pathways in Cln5 and 
Cln1 deficient mice. 
 
• To discover molecular interaction partners for Cln5  
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4 MATERIALS AND METHODS 
Materials and methods used in this thesis are described in the original publications. 
 
Materials and Methods Original publication 
Immunohistochemistry I, II, III 
Confocal microscopy III, IV 
Cortical thickness measurements II 
Counts on neuronal number II 
Culturing of COS-1 and HeLa cells IV 
Dissection and culturing of primary neurons III 
Gene expression pathway analysis I, III 
Gene expression profiling I, III 
Histological processing of mouse brain II 
In vitro binding assay (GST pulldown) IV 
Light microscopy I, II, III 
Locus specific gene expression analysis III 
Mouse brain lysate preparation  III 
Mouse brain tissue preparation  I, II, III, IV 
Protein detection by Western blot analysis III 
Protein detection by immunofluorescence  III, IV 
Quantitative thresholding image analysis II, III 
Real-time PCR I 
Regional volume measurements II 
RNA extraction I,III 
Transient transfections III,IV 
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4.1 Animals 
Homozygous mutant Cln5-/- and Cln1-/- mice were generated on a mixed 
C57BL/6Jx129SvEv strain background. The genotypes of all mice were determined 
by polymerase chain reaction of DNA from tail biopsies (Jalanko et al., 2005; Kopra 
et al., 2004). 
All animal experiments were conducted in accordance with international standards 
on animal welfare and with approved animal policies of the National Public Health 
Institute, Helsinki, with adequate measures taken to minimize pain or discomfort. 
 
THL — Research 6 50 Animal model and Molecular 
interactions of Cln5
4 Materials and Methods
  
5 RESULTS AND DISCUSSION 
5.1 The Cln5-/- mouse (I) 
Prior to this study, vLINCLFin had only been studied in human patients. The CLN5 
gene had been cloned and positioned on chromosome 13q21-q32. However, CLN5 
turned out to be a protein without any known functions or homologs (Savukoski et 
al., 1998). It was later shown to be a lysosomal protein (Isosomppi et al., 2002; Vesa 
& Peltonen, 2002), probably targeted to the lysosomes via the M6-P receptor 
pathway (Sleat et al., 2005; Sleat et al., 2007) Yet some uncertainty existed as to 
whether it is a soluble or transmembrane protein (Isosomppi et al., 2002; Vesa & 
Peltonen, 2002; Kyttala et al., 2006). As is the case with other NCL proteins, 
CLN5/Cln5 was proposed to have an additional function in the brain, due to the fact 
that in neuronal cells Cln5 appeared to additionally localize outside lysosomes in the 
neuronal cell soma and axons (Holmberg et al., 2004). 
Atrophy of both cerebellum and cerebrum had been observed in autopsies of CLN5 
patients (Tyynela et al., 1997). The cerebellar atrophy was rather severe, with almost 
complete destruction of the granule and Purkinje cells. Advanced loss of cortical 
neurons was also observed, with the remaining cells displaying pronounced storage 
enlargements. 
These results were nevertheless only mirroring the end stages of the disease. In order 
to elucidate the specific function of Cln5 and the defected cellular pathways, a more 
complete view and knowledge of earlier disease events was crucial. 
Mouse models for other NCL diseases were already available. The Cln1 (Gupta et 
al., 2001; Jalanko et al., 2005) Cln3 (Cotman et al., 2002; Katz et al., 1999; 
Mitchison et al., 1999), nclf (CLN6)(Bronson et al., 1998) and mnd (CLN8) 
(Bronson et al., 1993; Messer et al., 1993) mice  had all faithfully replicated the 
cellular phenotype of their human disease counterparts. 
In view of these results, it was meaningful to create a mouse model for vLINCLFin in 
order to study the molecular and cellular mechanisms of this disease in greater 
depth. 
The Cln5 knock-out mouse was generated by targeted deletion of exon 3 of the 
mouse Cln5 gene. The neomycin cassette inserted in exon 3, causes a frameshift 
mutation resulting in a premature stop codon. As a result only a truncated Cln5 
protein is predicted to be synthesized in the cells. It is however likely that the 
truncated protein is eliminated by nonsense-mediated decay (NMD), a cellular 
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mechanism that limits the synthesis of abnormal proteins in the cell (Holbrook et al., 
2004). The introduced mutation closely resembles the disease mutation found in a 
Swedish patient Glu253Stop. The homozygous mice did not show any birth 
anomalies and were born at a Mendelian frequency. The mice were fertile. The 
genotypes of all mice used in the subsequent experiments were determined by PCR. 
5.1.1 The Cln5-/- mouse mimics the vLINCL disease in man 
The Cln5-/- mice were followed from 5 weeks to 8 months of age and compared to 
their heterozygote and wild type (wt) littermates, to assess changes in their 
phenotype.  
The visual progression of the Cln5-/- mice was followed by a forelimb extension 
test. The forelimb-extension test is thought to measure visual ability, but it is a 
common method to detect severe cognitive dysfunction (Mangiarini et al., 1996). A 
progressive impairment in this test was evident around week 13 and severe loss of 
vision could be detected at the average of week 21. Wt and heterozygous mice 
showed no changes in vision (I; figure 2). This result was consistent to the loss of 
vision in human patients. 
In addition to the severe loss of vision, human patients suffer from other symptoms, 
such as epileptic seizures or motor abnormalities. Despite following Cln5-/- mice up 
to 8 months no other symptoms characteristic for human patients, could be detected.  
After the initial phenotypic characterization, the Cln5-/- mice underwent 
neuropathological assessments. The typical neuropathological finding in all NCLs is 
the accumulation of autofluorescent material in the CNS. The major storage 
component in vLINCLFin patients is subunit C of the mitochondrial ATP synthase 
complex and the ultrastructure of this storage material consists of rectilinear, 
curvilinear and fingerprint profiles. Therefore the Cln5-/- mice were assessed for 
accumulation of autofluorescent lipopigments.  
6 month old Cln5-/- mice exhibited prominent autofluorescence throughout the 
brain. The autofluorescent material was scattered throughout the whole cortex, 
except for lamina I. Storage material was also evident in the retina, hippocampus 
and in some nuclei of the midbrain. The autofluorescence was nevertheless not as 
obvious in the cerebellum. Elevated autofluorescence was already observed in 1-
month old animals; however, the amounts were distinctly less than in the older 
animals (I; figure 3). 
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Electron microscopic analysis was also preformed on brain sections of 3 month old 
mice, to be able to assess the ultrastructure of the storage material. Inclusion bodies 
were found in neurons of both cortex and thalamus, although not abundantly. They 
showed a mixture of lamellar bodies and both curvilinear and fingerprint profiles (I; 
figure 4). These results confirmed that the Cln5-/- mouse represents the human 
vLINCLFin disease accurately, with visual failure /cognitive dysfunction and typical 
ultrastructural findings. What is notable is that the cerebellum which is severely 
affected in human patients is relatively spared in the mouse model, with the cortex 
and thalamus appearing to be predominantly affected.    
Earlier studies on NCL patients, in conjunction with animal models, have shown 
evidence for progressive loss of GABAergic interneurons (Braak and Goebel 1978, 
1979; Cooper et al., 1999; Cooper, 2003; March 1995; Walkley and March 1993;  
Williams et al., 1977). Immunohistochemical stainings on 1- and 6- month old Cln5-
/- mouse brains were preformed to assess possible neuron loss and to address the 
nature of the degenerated cell type. Paraffin sections were stained with parvalbumin 
and calbindin, both markers for a subset of GABAergic interneurons. Compared to 
wt controls, a severe loss of both parvalbumin and calbindin positive interneurons 
were evident in the 6-month old Cln5-/- mouse (I; figure 5). The neuron loss was 
evident in several brain areas, including cortex, hippocampus, thalamus, midbrain 
and cerebellum. Within the cortex, the deeper laminae and entorhinal cortex were 
especially afflected by neuron loss. Loss of Purkinje cells was additionally evident 
in the cerebellum. Small changes in the immunoreactivity of both cortex and 
cerebellum could already be observed in 1- month old mice (I; figure 6).  
These findings have been replicated in many NCL mouse models including; Cln1, 
Cln3, Cln8 and Cln10, (Bible et al., 2004; Cooper et al., 1999; Jalanko et al., 2005; 
Pontikis et al., 2004; Pontikis et al., 2005; Shimizu et al., 2005). In Ctsd-/- mice, 
the reason for this specific vulnerability of GABAergic interneurons might be due to 
reduced GABA levels, resulting from increased lysosomal degradation of GAD67. 
GAD67 is an enzyme that normally participates in the synthesis of GABA (Shimizu 
et al., 2005). However, how this applies to the rest of the NCLs is as yet unknown. 
Remarkably, several lysosomal storage disorders have been reported to show loss of 
GABAergic interneurons and, therefore, this phenomenon is likely to reflect 
lysosomal dysfunction (Walkley et al., 2009). 
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5.1.2 The old Cln5-/- mouse suffers from neurodegeneration, 
inflammation and loss of myelin  
No function has yet been assigned for Cln5 and nothing is known about any specific 
cellular mechanisms that result in vLINCLFin. To get a more detailed description of 
the progression of the disorder at the gene expression level, we preformed 
microarray analysis of the Cln5-/- cortex. As the forelimb extension test for visual 
symptoms appeared positive around week 13, we wanted to assess gene expression 
changes during the active disease process. Therefore 3- and 4.5- month old mice 
were chosen for this analysis. Wt littermates were used as controls. The gene 
expression analyses were performed using the Affymetrix microarrays (Murine 
Genome U74Av2), which enables the measurement of 14 000 known genes. To 
average out the variability between different mice, we pooled RNA from two mice 
/genotype/age. The raw data was analysed with the MAS 5.0 (Affymetrix) software. 
We chose the fold change of 2 as a cut-off point, which gave us 16 differentially 
expressed genes in the 3-month old dataset and 68 differentially expressed genes in 
the 4.5 month dataset (I; table 1).  
Since the number of differentially regulated genes was so small in the 3.5 month 
data, we decided to combine the resulting gene lists for further analysis. This was to 
categorize the combined results according to their Gene Ontology (GO) 
classifications, using the publicly available Gene Ontology Tree Machine tool-kit 
(Ashburner et al., 2000). Again, due to the limited number of genes, we included 
gene expression changes smaller than 2-fold, based on our hypothesis that many 
small changes in a pathway, especially in the brain, can together result in large 
changes. This analysis yielded three major pathways or structural components with 
significantly more genes observed than expected; Inflammation/defence 
mechanisms, Components of myelin, Neurodegenerative pathway (Fig. 3, I; table 2). 
These results are in line with the knowledge about the actual disease process: Brain 
autopsies from vLINCLFin patients reveal loss of myelin, neurodegeneration and 
inflammation.  
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Figure 3. Affected 
pathways in the 6 month 
old Cln5-/- mouse 
 
 
5.2 Histological characterization of the Cln5-/- mouse brain (III) 
The function of the Cln5 protein remained elusive and except for the basic 
characterization of the Cln5-/- mouse, much was unknown about the brain pathology 
of the mouse. Many other NCL mouse models had already been histologically 
characterized, and a common theme seemed to evolve from this data. Detailed 
pathological analyses from Cln1 (Bible et al., 2004), Cln3 (Pontikis et al., 2004; 
Pontikis et al., 2005) and Ctsd (Partanen et al., 2008) deficient mice had highlighted 
the thalamo-cortical pathways as a starting point for NCL pathology. In these NCL-
models neurodegeneration combined with reactive gliosis had been shown to initiate 
in the thalamus and subsequently move to the cortex. To gain a detailed view of the 
brain pathology of the Cln5-/- mouse we therefore performed stereological analyses 
of Cln5-/- mice at different stages of the disease. As previous results from other 
NCLs had highlighted the thalamo-cortical pathways, we focused our analysis on 
this part of the brain.   
5.2.1. Neurodegeneration is initiated in the cortex of Cln5-/- mice 
We first utilized 12 month old Cln5-/- mice and controls to analyze for progressive 
neurodegenerative changes in the cortex. Cavalieri estimates of regional volume 
revealed a widespread atrophy of the Cln5-/- brain. The affected areas included 
cortex, hippocampus, striatum and thalamus (II; figure 1A). No significant changes 
were, however, found in the volume of hypothalamus and cerebellum. 
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Late stage cortical atrophy is a common feature in all NCLs, both in humans and in 
mice. It is, however, mostly confined to specific regions (Bible et al., 2004; Kielar et 
al., 2007). In order to elucidate if any particular areas of the cortex were more 
severely affected than others, we made thickness measurements of different 
cortical regions, observing that the thinning was equal within all regions measured; 
primary motor cortex (M1), somatosensory barrelfield cortex (S1BF), primary visual 
cortex (V1) and late entorhinal cortex (Lent) (II; figure 1B). These results would 
suggest that cortical atrophy was widespread rather than regionally specific, 
providing evidence that the pathology of Cln5 differs in some way from other forms 
of NCLs. 
Next, we wanted to investigate whether the observed thinning was uniform within 
all laminae of the cortex, by making a series of lamina specific thickness 
measurements. The results showed that the thinning was in fact lamina specific. 
Lamina V was affected through all measured cortical regions, while laminae IV and 
VI were affected in all regions bar M1. The rest of the measured laminae expressed 
a complex variability of changes in thickness; a reduced thickness within some 
areas, whilst an increased thickness in others. The increased thickness could be 
caused by “swollen” cells that have become enlarged due to large amounts of 
storage material within the cells. The changes in lamina thickness within different 
areas of the cortex can be viewed in Fig 4. 
 
Figure 4. Lamina specific thickness in 
the cortex of 12 month old Cln5 -/- 
mice 
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Since we had observed that both volume and thickness were reduced in the cortex of 
12 month old Cln5-/- mice compared to controls, it was important to investigate 
possible changes in neuronal number. Other NCL mouse models had revealed that 
two specific cortical regions are affected by neuronal loss in the late stages of 
disease. These regions were S1BF and V1, the two target regions of the thalamic 
relay neurons that originate from ventral posterior thalamic nucleus (VPM/VPL) and 
dorsal lateral geniculate nucleus (LGNd), respectively. These thalamic areas were 
the ones that were initially affected in other NCL mice. We therefore focused our 
analysis on these two cortical regions (S1BF and V1), and to measure laminae IV-
VI, which are the laminae that receive information or send feedback to the thalamus. 
Unbiased optical fractionator estimates of Nissl stained granule neurons of 12 month 
old mice revealed a significant neuron loss in almost all regions analysed. Only 
lamina VI in S1BF did not show reduction of neuronal number at this age. We 
proceeded with our analyses, using 4 month old Cln5-/- mice. Interestingly, and 
contrary to all other NCL models, we witnessed a reduction of cortical neuronal 
number already by 4 months. There was a significant reduction of neuronal number 
in lamina V, evident in both S1BF and V1. The rest of the laminae in S1BF 
appeared to be spared, but a reduction of neuronal number was also evident in 
lamina IV of the visual cortex (V1) (Fig 5). This suggests that even though both 
areas of cortex are already affected by this early age, the neuron loss appears to 
occur earlier in the visual system. This relatively early cortical neuron loss differs 
from previous results from other NCL models, where cortical atrophy is evident 
only in late stages of the disease.  
5.2.2. Thalamus is relatively spared 
In the light of the previous observations regarding different NCL mouse models, we 
originally anticipated that there would be significant early neuron loss in the 
thalamus of the Cln5-/- mice. Until now it had been evident that the NCL pathology 
starts in the thalamus, subsequently spreading to the cortex. We used unbiased 
optical fractionator estimates of Nissl stained sections within three thalamic nuclei. 
These nuclei relay different sensory modalities to the cortex; the VPM/VPL which is 
connected to S1BF (somatosensory), the LGNd which is connected to V1 (visual) 
and the medial geniculate nucleus (MGN) which is connected to the auditory cortex. 
Again, contrary to our hypothesis there was no evidence of early neuron loss in the 
thalamus. There was significant loss of neurons in the VPM/VPL and the LGNd, but 
it was not evident before the age of 12 months, whereas the MGN seemed to be 
completely spared (Fig 5). These results suggest a reversed timing of pathological 
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events in the Cln5-/- mouse, compared to other NCL models. In the Cln5-/- mouse 
neurodegeneration occurs first within the cortex and only subsequently in the 
thalamus. It is known that lamina V of the S1BF projects to other subcortical 
structures, whereas lamina IV receives most of the imput from the thalamus and 
lamina VI projects back to the thalamus (Kandel et al., 2000). It appears that the 
neurodegeneration is initiated in lamina V, therefore possibly affecting the other 
cortical layers by interfering with the intercortical projections. However, the next 
lamina to be affected is lamina IV, receiving information from the thalamus. One 
possibility is that the neuronal loss in lamina IV is due to thalamus mediated events. 
This is supported by MEG recordings in human vLINCLFin patients indicating 
inbalance between excitation and inhibition (Lauronen et al. 2002).  
Previous data have shown that CNS expression patterns are similar for Cln1 and 
Cln5 (Heinonen et al., 2000b). Moreover, we have shown that both Cln1 and Cln5 
share the same affected cellular pathway (see III and chapter 5.3 in this thesis). 
Furthermore our recent results have revealed that Cln1 and Cln5 interact with each 
other (see IV and chapter 5.4 in this thesis). Future studies of the actions of these 
two connected proteins should provide answers as to why they affect the 
thalamocortical system so differently. 
  5.2.3 The glial responses become evident before neurodegeneration 
As mentioned earlier, mouse models of NCL share several common pathological 
features that include thalamo-cortical atrophy and pronounced early gliosis. Mouse 
models of NCL have been shown to display localized and progressive glial 
activation, which usually precedes neurodegeneration (Cooper et al., 2006). This 
reactive gliosis has been pronounced within the thalamo-cortical pathways. To 
determine if Cln5-/- mice share this phenotype with other NCL-mouse models, we 
stained sections from 1-, 4- and 12- month old mice and controls. Since reactive 
gliosis is characterized by hypertrophy of astrocytes and by proliferation of 
microglial cells and astrocytes, we imunostained brain sections of Cln5-/- and 
control mice for both of these cell types. For astroglia, we utilized the well 
characterized glial fibrillary astrocytic protein (GFAP), a member of the class III 
intermediate filament protein family, expressed in astrocytes and certain other 
astroglia in the central nervous system (Reeves et al., 1989). For microglial staining, 
we used the F4/80 protein, a cell surface glycoprotein that is a member of the EGF 
TM7 family of proteins, expressed on a wide range of mature tissue macrophages 
(McKnight & Gordon, 1998). We performed quantitative thresholding image 
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analysis for immunostainings of the thalamus, the S1BF and V1 regions of the 
cortex of Cln5-/- mice. 
Although of a small magnitude, upregulation of GFAP immunoreactivity was 
already significant in the VPM/VPL nucleus of the thalamus and S1BF of the cortex 
of 1 month old Cln5-/- mice.  The staining became more pronounced with increased 
age. At 4 months Cln5-/- mice displayed prominent GFAP immunoreactivity in the 
VPM/VPL nucleus of the thalamus and within all laminae of both the S1BF and V1 
areas of the cortex, except for lamina IV. However, it was notable that the staining 
was more intense in the thalamus.  At 12 months of age, both VPM/VPL and LGNd 
nuclei of the thalamus revealed intense immunoreactivity for GFAP, as did all 
laminae of both the S1BF and V1 of the cortex (II; figure 5)(Fig 5).  
The quantitative threshold image analysis on F4/80 stained sections revealed no 
specific staining compared to controls in 1 or 4 month old Cln5-/- mice. However at 
12 months of age a pronounced statistically significant staining could be seen in 
both the cortex (S1BF) and the thalamus (VPM/VPL) of Cln5-/- mice (II; figure 6).  
Reactive gliosis is usually interpreted as a response to neurodegeneration. An 
alternative hypothesis implicates a protective role for GFAP upregulation as a 
response to very early changes, prior to neuronal degeneration, such as,  supporting 
neurons by exporting glucose to them, minimizing neuronal damage by regulating 
harmful glutamate levels, mediating repair, promoting remyelinisation as well as 
regulating neurogenesis during development (reviewed in (Carmen et al., 2007; 
Liberto et al., 2004). Early glial responses have been evident in multiple forms of 
NCLs (Bible et al., 2004; Kielar et al., 2007; Oswald et al., 2005; Pontikis et al., 
2005). In other NCL models this early gliosis occurs in the same areas of the brain 
as where the neuron loss subsequently takes place. However, this is not the case in 
Cln5-/- mice. The neuron loss starts in the cortex and can only later be detected in 
the thalamus at 12 months of age. Contrary, the reactive gliosis is evident in the 
thalamus already at the age of 1 month; months before any neuron loss can be 
observed. This data suggests that there could be some defects in the interplay 
between astrocytes and neurons, consistent with the suggestions made for other 
NCLs that imply protective glial responses occurring prior to neurodegeneration. 
Although this is plausible, we cannot rule out that the early astrocytic activation, 
unique for Cln5-/- mice, could be explained by other means, and may even be 
related to the function of Cln5 itself. 
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Figure 5. Reduced neuronal number and reactive gliosis in the Cln5-/- mouse brain 
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5.2.4 Loss of myelin occurs already during early stages of the disease 
As loss of myelin is a general feature in vLINCLFin patients (Holmberg et al., 2000; 
Rapola et al., 1999) we investigated if this feature manifests in Cln5-/- mice, by 
performing quantitative thresholding image analysis on Luxol fast blue (LFB) 
stained sections. LFB is an alcohol soluble stain, for the lipoproteins in the myelin 
sheath. Both Corpus callosum (cc) and cerebellum (cb) were measured. Significant 
loss of myelin in the corpus callosum could already be observed at the age of 1 
month. The same loss could also be seen at the age of 4 months. An even greater 
loss of myelin was evident in the cerebellum at the age of 1 month, and the LFB 
staining was upregulated at the age of 4 months in the same region. This is most 
likely due to the fact that LFB stains for lipids, and severe lipofuscin storage can be 
observed in the Cln5-/- brain at the age of 4 months (unpublished data)(Fig 6). 
 
Figure 6. 
Changes in the 
myelin staining 
in the Cln5-/- 
mouse compared 
to wildtype (WT) 
 
 
 
 
 
These results are in line with previous findings from vLINCLFin patients. They are 
also consistent with our results from gene expression proliling analyses of Cln5-/- 
mice, that show that the expression of many genes connected to myelinization are 
downregulated (see 5.1.2 and 5.3.1). The loss of myelin is apparent already at the 
age of 1 month. Earlier time-points were not included in the original experimental 
design, so it is not known whether the reduced LFB staining reflects the loss of pre-
existing myelin, or if the whole myelinization process itself is faulted and therefore 
delayed. The loss of myelin is concurrent with the emerging reactive gliosis in the 1 
month old Cln5-/- mouse brains, potentially implying a connection between these 
two events. It has previously been shown that reactive astrocytes promote 
remyelinization in the brain (Carmen et al., 2007; Liberto et al., 2004). Additionally, 
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patients with Alexander disease, which is caused by mutations in the GFAP protein, 
also suffer from hypomyelinization (Li et al., 2002). Therefore, this could present 
another explanation for early astrocytic activation in the Cln5 deficient brain; the 
reactive gliosis at this point could be a secondary event resulting from loss of 
myelin. The role of myelin and the myelin producing oligodendrocytes seems to be 
emerging behind NCL pathology. Magnetic imaging analyses of NCL patients with 
varied types of NCL disorders, have implicated loss of myelinization (Haltia 2003). 
Furthermore, a recent MRI study of several NCL mouse models also implicated 
major changes in the white matter, suggesting a prominent role of myelin related 
events in NCL (Haapanen et al., manuscript in preparation).  
5.3 Cln5 shares a common molecular pathway with Cln1 (II) 
Despite the identification of many genes mutated in NCLs, there were still many 
unanswered questions. How do mutations in so many different genes result in 
clinically and histopathologically similar diseases? Why is the CNS particularly 
vulnerable to disease? Is there a common defected pathway behind NCLs, resulting 
in similar clinical findings? To find answers to some of these questions, we 
performed gene expression profiling analyses on both Cln5-/- and Cln1-/- mouse 
models. The Cln1-/- mouse had also been generated by our laboratory (Jalanko et 
al., 2005) and represented a mouse model for INCL, the infantile form of NCL. 
Initial gene expression profiling analyses of both of the models had already been 
performed (I, (Jalanko et al., 2005)), but those analyses concentrated on time points 
representing later stages of the disease. Six month old Cln1-/- mice exhibited gross 
upregulation of inflammation related genes and 3 and 4.5 month old Cln5 -/- mice 
displayed changes in genes that where related to inflammation, myelin integrity and 
neuronal degeneration. To identify early and progressive changes in genes and 
metabolic pathways that may contribute to the neurological phenotype observed in 
the Cln1-/- and Cln5-/- mice we chose 1 and 4 month old mice for our present 
analysis and used RNA from the cortex. We used the Affymetrix MOE 430A gene 
chips representing close to 14,500 annotated genes and more than 4300 ESTs. 
We initially analyzed both mouse models separately, in order to find gene 
expression changes that were specific to each disorder. 
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5.3.1 Gene expression changes in the Cln5-/- mouse 
Analysis of the 1 month old Cln5-/- mouse revealed 76 upregulated genes and 206 
downregulated genes. The most upregulated gene was adenylate cyclase-associated 
protein 1 (Cap1, 3.9-fold) and the most downregulated gene was chemokine (C-C 
motif) ligand 21 a (Ccl21a, -1,7 - fold). 
At 4 months, 34 upregulated and 80 downregulated genes were identified. The most 
prominent change was seen in the kinesin family member 5C (Kif5c), which was -
6.4-fold downregulated. Other genes that were downregulated by greater than 5-
fold, included DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 (Ddx6) and G-protein-
coupled receptor family C, group 5, member B (Gprc5b). The most upregulated 
gene was dentatorubral-pallidoluysian atrophy protein (Drpla) with a fold change of 
4.1. 
Single gene changes are not however, usually as informative as the analysis of 
whole biological pathways. We therefore proceeded to analyze these using a custom 
made non-parametric pathway analysis algorithm. In the 1 month old Cln5-/- mice 
we discovered that pathways related to regulation of cell adhesion, RNA processing 
and transcription and phosphorylation were affected. Pathways related to 
myelination and camera eye development were affected in the 4 month old Cln5-/- 
mice (III; figure 2). These results were expected because vLINCLFin patients are 
known to suffer from loss of vision and hypomyelinization (Holmberg et al., 2000; 
Rapola et al., 1999). Our previous results from immunohistochemical studies and 
from gene expression profiling (II, I) also revealed that the Cln5-/- mouse is 
affected by loss of myelin. We have additionally shown that neuron loss, typical for 
NCLs, starts in the visual cortex (V1) in Cln5-/- mice at the age of 4 months (II). 
This corroborated our novel microarray results. We could therefore assume that the 
results from the 1 month old mice are, to a degree accurate and related to the 
ongoing disease process, although there is no simple way to connect these 
microarray results to any “visible” defects in the young presymptomatic mouse. Our 
previous results had revealed ongoing neuronal death in the Cln5-/- mouse brain, 
already at the age of 4 months (II). No gene expression changes were, however, 
evident which would point to any activated apoptotic or autophagic signal cascades 
in the Cln5-/- mouse brain, most likely due to the fact that apoptosis or autophagy 
might be only secondary events resulting from neuronal cell death initiated by other 
mechanisms.  
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5.3.2 Gene expression changes in the Cln1-/- mouse 
 The analysis of the 1 month old Cln1-/- mouse revealed 261 upregulated and 156 
downregulated genes. The most upregulated gene was cytotoxic granule-associated 
RNA binding protein 1 (Tia 1), with a fold change of 1.6. The most downregulated 
genes included Cln1 and protein tyrosine phosphatate receptor type F (Ptprf), with 
fold changes of -3.5 and -2.2, respectively. When analyzing the 4 month old Cln1-/- 
mice we discovered 137 upregulated and 27 downregulated genes. The most 
upregulated gene, with a 32-fold increase in expression was Cap1. Interestingly, 
Cap1 was discovered to be the most upregulated gene also in 1 month old Cln5-/- 
mice. The astrocyte related Gfap was another prominently upregulated gene, with a 
fold change of 16.6. The most downregulated genes included inactive X specific 
transcripts (Xist), Gprc5b, and Ptprf, with fold changes of -7.0-, -3.7- and -3.3, 
respectively. Ptprf had already been implicated in 1 month old Cln1-/- mice, and this 
result suggested that this gene or protein might be important in the Cln1 pathology. 
We further noted that both Gprc5b and Ptprf were also affected in Cln5 deficient 
mice, suggesting a connection between these two NCL disorders. 
The pathway analysis of 1 month old Cln1 defected mice revealed affected pathways 
that were connected to neuronal entities, signal pathways related to phosphorylation 
and  calcium ion homeostasis. The calcium homeostasis pathway was also 
significantly affected in 4 month old Cln1-/- mice, in addition to inflammation 
associated pathways. Affected categories at this age included also cytoskeleton and 
lysosomes (III; figure 2). Again it seems as though the data from the 4 month old 
mice accurately supports our previous observations. Inflammation is a common 
feature in all NCLs and since PPT is a lysosomal enzyme, its alteration would be 
expected to affect the function of lysosomes. Changes in transcripts encoding 
calcium binding proteins have previously been shown by gene expression profiling 
of cultured Cln1-/- neurons. Further, functional studies revealed that Cln1-/- cells 
exhibited an improved ability to recover after a potentially excitotoxic stimulation 
with glutamate, as compared to wt cells (Ahtiainen et al., 2007). 
5.3.3 Similar changes in gene expression suggest aberrations in a pathway 
regulating growth cone stabilisation 
In order to search for common affected pathways between Cln5-/- and Cln1-/- mice, 
we compared both mouse models datasets to each other. We used gene lists of 
differentially expressed genes made separately for each model and each age group, 
comparing them so as to identify genes that showed expression changes in both of 
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the disease models. This comparison analysis revealed 51 genes that were altered in 
both Cln5 and Cln1 deficient mice (III; table 1). After extensive literature searches 
we identified several of these 51 genes to be critical in neuronal growth cone and 
cytoskeletal dynamics. We then went through the separate gene lists for each mouse 
model again, in order to find additional genes that could be linked to this affected 
pathway. As a result we revealed that many genes were differently expressed in the 
same pathway, in both Cln5-/- and Cln1-/- mice. Within this common pathway gene 
expression changes between the two mouse models could be identical, opposite, or 
only in one strain. The affected pathway is illustrated in Fig 7. Interestingly, several 
of the genes affected in both mouse models, especially those involved in 
phosphorylation, were found to be in a coexpressed gene cluster with Ppt1, the gene 
disrupted in the Cln1-/- mouse (III; figure 3). Several studies have implicated that 
coexpressed gene clusters represent genes potentially operating in the same 
metabolic pathway (Pal & Hurst, 2004), thus supporting the important role of 
receptor phosphorylation in both Cln1 and Cln5 mediated functions.  
The combined analysis especially highlighted the downregulation of LAR PTP, 
implicated in neurite outgrowth, modulation of synapse formation and synaptic 
vesicle release (Stryker & Johnson, 2007). Interestingly, PPT1 expression is 
reported to be simultaneous with synaptogenesis (Isosomppi et al., 1999; Suopanki 
et al., 1999) and evidence of affected synaptic vesicles have been reported in the 
Cln1-/- mouse (Virmani et al., 2005). Additionally, we could detect upregulation of 
Src tyrosine kinase and the cyclase-associated protein Cap1. Thus, a link to the Src 
family kinase Fyn, which is implicated in several neurodegenerative conditions such 
as Alzheimer and Prion diseases (Lee 2005; Santuccione 2005), could be 
established. The gene expression profiling revealed a downstream linkage to the 
cytoskeleton, especially highlighted in the Cln5-/- mouse where we could 
demonstrate disturbed actin expression also at protein level. Cln3, the gene defected 
in JNCL, is also linked to cytoskeletal abnormalities (Luiro 2006). It will be 
interesting to determine if the cytoskeletal defects are common for all different 
NCLs, and wether they are responsible for deficiencies in the intracellular 
trafficking. 
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Figure 7.  
A common 
affected pathway 
in Cln5 and Cln1 
deficient mice. 
Upregulated 
genes are marked 
in red, whereas 
downregulated 
genes are marked 
in green. Genes 
with no 
difference in their 
expression are 
coloured gray. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microarray methods are essentially for screening. They measure levels of messenger 
RNA (mRNA). Although it can not directly be assumed that there is a correlation 
between mRNA and protein levels, it might be reasonable to conclude that a 
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different expression level of a specific mRNA in a disease is an indication for some 
type of abnormality in eithe the encoded protein, an affiliated structure or function, 
and deserving of further investigation (Konradi C, 2005). However, it has to be 
noted that there are several limitations to microarrays. A major limitation is a 
decreased sensitivity of the arrays to detect genes with low expression levels. 
Another drawback is that microarrays do not measure posttranslational 
modifications, such as phosphorylation (Bunney et al., 2003). It must also be 
remembered, when working with the brain, that the brain tissue is heterogeneous 
containing many different nerve cells. This may decrease the sensitivity of 
microarrays by masking changes in gene expression. These issues should be kept in 
mind, when validating microarray data. 
 
5.3.4 The cytoskeleton is affected  
As our data from gene expression profiling implicated defects in several genes and 
pathways linked to the cytoskeleton, we further investigated the integrity of the 
cytoskeleton in the Cln1 and Cln5 deficient mice by analysing both localization and 
quantity of two known cytoskeletal markers; actin and tubulin. For this purpose, we 
preformed double immunofluorescence (IF) analysis on E15 primary cortical 
neurons from wt, Cln5 and Cln1 deficient mice. Although the gene expression 
profiling was performed on brain tissue, we used neuronal cell cultures, due to the 
fact that double immunofluorescence analysis techniques are more informative when 
performed on fixed cells. 
The results from the Cln1-/- neurons displayed a loss of both actin and ß-tubulin 
staining in the cell soma compared to wt, whereas the growth cones of the mutant 
mouse neurons displayed greater and distinct staining by actin than the wild-type 
neurons (III; figure 4A).  
The immunofluorescence analysis of Cln5-/- neurons also revealed cytoskeletal 
defects. The actin staining was relatively more intense in both the cell soma and 
processes, when compared to wt neurons. No changes were, however, evident in the 
ß-tubulin staining of Cln5 deficient neurons compared to wild-type (III; figure 4A). 
To elucidate the intracellular protein levels and localizations of these proteins we 
preformed Western blot (WB) analysis on both soluble and membrane-bound 
intracellular fractions made from Cln5-/-, Cln1-/- and wt mice. The fractions were 
prepared from 4 month old mice brains and stained with markers for actin and 
tubulin. By fractionating the cell lysate we were able to assess whether the proteins 
of interest were in soluble forms, or bound to cellular membranes. No changes were 
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seen in the quantity of actin staining between the two models (data not shown). 
However, the ß-tubulin staining was almost completely absent in the Cln5-/- mouse 
(III; figure 5B). To analyse the Cln5-/- mouse further, we proceeded with 
immunohistochemical analyses on actin and tubulin stained Cln5-/- whole brain 
sections. The quantitative threshold image analysis of these sections revealed that 
the actin staining was significantly increased in 1 month old Cln5-/- mice, whereas 
the ß-tubulin staining was significantly decreased in 4 month old Cln5-/- mice (III; 
figure 4B). These results confirm our previous microarray results and prove that the 
cytoskeleton is indeed affected, particularly in Cln5, but also in Cln1 deficient mice.  
5.3.5 The growth-cone is affected 
When comparing the gene expression profiling data of Cln5-/- and Cln1-/- deficient 
mice, a pathway connected to neuronal migration and the growth cone emerged. We 
had already noted that the cytoskeleton is affected resulting from expression changes 
in genes related to this pathway and further demonstrated both quantitative and 
qualitative changes in the amounts of intracellular membrane-bound and soluble 
cytoskeletal proteins. Next we analysed for possible aberrations in the intracellular 
staining of growth-cone related proteins using immunofluorescene staining and 
confocal microscopy. We chose three well known markers for growth-cone 
assembly; Gap-43, synapsin and Rab3 for our analysis. Rab3 was, in addition, 
shown to be differentially expressed in our microarray data.  Gap-43 is expressed at 
high levels in neuronal growth cones during development and during axonal 
regeneration. Even though it is not essential for axonal outgrowth or growth cone 
formation per se, it is required at certain decision points, such as the optic chiasm. It 
is thought that Gap-43 serves to amplify pathfinding signals from the growth cone 
(Strittmatter et al., 1995). Synapsin is a synaptic vesicle-associated protein, 
participating in synapse formation, regulation of the synthesis of other synaptic 
vesicle proteins and promotion of neurotransmitter release (Qin S 2004). Rab3 is 
known to regulate the fusion of synaptic vesicles (Geppert et al., 1997). Rab3 and 
synapsin are known to interact. Synapsin stimulates Rab3a recruitment to synaptic 
vesicles, whereas Rab3 inhibits the binding of synapsin to actin (Giovedi et al., 
2004). 
When analysing the Cln5-/- mice an abnormal staining of synapsin was observed. In 
wt mice the synapsin staining was evenly distributed, whereas in Cln5-/- mice the 
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staining was dotted around the cell soma. No other irregularities were however seen 
in the IF staining of Cln5-/- mouse neurons (III; figure 5A). 
Next we analysed the Cln1-/- neurons. No changes were observed in the synapsin 
staining in Cln1-/- mice. Conversley, both of the other markers appeared abnormal. 
The Gap-43 staining, which stains axonal varicosities in wt mice, displayed a 
pronounced staining pattern around the cell soma in Cln1-/- mice and was almost 
absent from the varicosities in these mice. Rab3 staining was unusually faint in 
Cln1-/- neurons compared to wt, suggesting reduced amounts of this protein (III; 
figure 5A). 
To examine the intracellular levels of membrane-bound and soluble synapsin, Gap-
43 and Rab3 we proceeded with WB analyses on both soluble and membrane-bound 
intracellular fractions from Cln1-/- and Cln5-/- mice. Although, IF staining of 
synapsin appeared abnormally distributed in Cln5-/- neurons, no detectable change 
was observed by WB in the intracellular protein levels of this marker. However, the 
WB analysis revealed Rab3 to be almost completely absent from the cytoplasmic 
fraction in Cln5-/- mouse brain lysates. Additionally, no changes were seen in the IF 
staining of Gap-43, whereas a more pronounced membrane localization of this 
marker was evident in WB analysis (III; figure 5B). 
We confirmed our previous result of pronounced IF staining by Gap-43 around the 
Cln1-/- neuron cell soma through WB analysis. Additionally, Gap-43 was enriched 
in the membrane fraction of Cln1-/- brain lysates. The Rab3 protein staining 
appeared unchanged, even though the IF staining suggested a reduced amount of 
protein in the cells.  However, although we had not seen any apparent changes in the 
synapsin IF staining, the WB analyses indicated that the amounts of synapsin were 
greatly reduced in the brain lysate from Cln1-/- mice (III; figure 5B). 
These results are in line with our microarray results, indicating a functional defect in 
the growth cone. We demonstrated on a cellular level that both the cytoskeleton and 
the growth cone are indeed affected. Gap-43 is palmitoylated (Liu et al. 1994) and 
has been shown to be depalmitoylated by PPT1 in vitro (Cho et al., 2000). Abnormal 
accumulation of Gap-43 in the ER has previously been implicated in INCL (Kim et 
al., 2006). Here we showed that Gap-43 was abnormally accumulated in Cln1-/- 
mice in the neuronal cell membrane, and to the membrane fraction of brain cell 
lysates. 
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5.4 CLN5 interacts with CLN1, CLN2, CLN3, CLN6 and CLN8 (IV) 
Our finding of common affected pathways in Cln1-/- and Cln5-/- mice supported the 
fact that phenotypically similar NCL diseases may be linked by molecular 
interactions. CLN5 has previously been shown to interact with CLN2 and CLN3, 
based on coimmunoprecipitation and in vitro binding assays (Vesa et al., 2002a), but 
the significance of this interaction has remained unknown. Furthermore, Bessa and 
colleagues had demonstrated that the expression of both CLN3 and CLN5 was 
reduced in CLN2 patients and that the expression of CLN3 is reduced in CLN5 
patients (Bessa et al., 2006). Taken together, all this data is suggestive of a common 
function or pathway for the NCL proteins. Therefore, we wanted to analyse if CLN5 
has more interction partners among the NCL proteins, and particularly if it interacts 
with CLN1. 
5.4.1 The interaction between CLN5 and other NCL proteins 
The possible interaction of CLN5 with other NCLs was investigated by GST pull-
down experiments. A GST-Cln5 fusion protein expressing the full length mouse 
Cln5, but lacking the signal sequence (GST-Cln526-341), was used to pull down 
endogenous NCL proteins from both mouse brain extract and HeLa cell lysates. We 
additionally used overexpressed proteins from lysates of transiently transfected 
COS-1 cells, in order to be able to monitor for interactions that may go undetected 
endogenously due to the naturally low levels of NCL proteins. The analyses showed 
that in addition to CLN2 and CLN3, CLN5 does interact with CLN1/PPT1, CLN6 
and CLN8. Another lysosomal protein LAMP-1 was used as a negative control, and 
did not show any binding to CLN5 (IV; figure 1).  
5.4.2 The interaction between CLN5 and CLN1 is strong and occurs 
already in the ER  
To assess possible functional links between CLN1/Cln1 and CLN5/Cln5 we 
compared the localization of PPT1 in both Cln5-/- and wt mouse fibroblasts and 
overexpressed them together in HeLa cells. The cells were transiently transfected 
and fluorescently labeled with PPT1 and /or CLN5 specific antibodies, in addition to 
organelle specific markers. No changes where, however, seen in the lysosomal 
localization of PPT1 in CLN5 deficient fibroblast, or when overexpressed together 
with CLN5 in HeLa cells (IV; supplement 1). 
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We then wanted to see if defects in the transport of CLN5 would somehow affect the 
localization of PPT1. To investigate this, we created a trafficking deficient CLN5 
construct (TD-CLN5) by inserting an intramolecular flag-tag (CLN5-flag330) into 
the protein. This causes the TD-CLN5 to remain in the ER. Coexpression of both wt 
PPT1 and the TD-CLN5 resulted in the retention of PPT1 in the ER, indicating that 
the interaction between CLN5 and PPT1 is strong and occurs already in the ER. As a 
control we overexpressed PPT1 together with the trafficking-deficient CLN3-
flag434 construct. However, CLN3-flag434 did not affect the lysosomal trafficking 
of PPT1 (IV; figure 2). 
 The most common vLINCLFin disease mutation is the CLN5FinMajor (Tyr392X), 
which results in a truncated polypeptide lacking 16 amino acids from the C-terminus 
(Savukoski et al., 1998). It has previously been shown that this mutation causes the 
CLN5 protein to be retained in the ER and Golgi compartment (Isosomppi et al., 
2002). To evaluate if the interaction between CLN5FinMajor and PPT1 would affect 
the transport of PPT1, CLN5FinMajor and wt PPT1 were overexpressed together in 
HeLa cells. Intriguingly, we noticed that the normally ER/Golgi retained 
CLN5FinMajor was clearly localized to the lysosomes (fig 8, IV; figure 4). This 
indicates that the overexpressed PPT1 is still able to interact with mutated CLN5 
and facilitate the transport of the mutated protein to its correct localization in the 
lysosomes. To verify this result we repeated the experiment also in human 
neuroblastoma cells (SH-SY5Y), where the same effect was detected (IV; 
supplement 2). Our recent, unpublished results by Schmiedt and Bessa have further 
revealed that overexpressed PPT1 is able to facilitate the correct transport of CLN5 
proteins that carry all the other known vLINCLFin disease mutations.  
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Figure 8. Co-expression of wt CLN5, CLN5FinMajor and wt PPT1/CLN1 in HeLa 
cells.WT-PPT is able to transport the mutated Cln5 FinMajor, normally residing in 
the ER, to the lysosomes. 
5.4.3 Both CLN5 and CLN1 interact with F1-ATP synthase 
Lyly and colleagues have previously shown that CLN1 interacts with the F1-
complex of the mitochondrial ATP synthase (Lyly et al., 2008). In addition to its 
normal localisation in the mitochondria, F1- ATP synthase has been found on the 
surface of several different cell types (Kim et al., 2004; Martinez et al., 2003; Moser 
et al., 2001),where it can act as a receptor, for example for Apolipoprotein A-1 (Apo 
A-1). The amount of ectopic F1-complex (Alpha and beta subunits) were shown to 
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be incresed in Cln1-/- neurons, and consequently, Apo A-1 uptake was increased 
(Lyly et al., 2008), pointing to disturbances in cholesterol metabolism. 
As we detected an interaction between CLN5 and PPT1, we wanted to investigate if 
CLN5 would also interact with the F1- ATP synthase. GST-CLN5 was used to pull 
down proteins from an enriched lysosomal/mitochondrial fraction prepared from 
mouse liver. We were able to show that CLN5 does interact with both - and -
subunits of the F1-complex (IV; figure 7). In order to determine if the interaction 
between CLN5 and the F1-complex was mediated by PPT1, or vice versa, we 
repeated the experiment using cell lysates from both Cln1 and Cln5 deficient mice. 
We were able to show that both CLN5 and PPT1 were able to interact with the F1-
complex without the presence of each other (IV; figure 7, fig 9), further 
strengthening our previous finding of the interaction between CLN5 and PPT1. This 
raises the question of whether there are also disturbances in cholesterol metabolism 
in the Cln5 -/- mouse. Cholesterol is known to be an important component of 
myelin. Our observations of defects in the myelination of nerve fibers in the Cln5-/- 
mouse brain (see I, II) now link these findings.  
5.4.4 The functional consequences of the interactions between CLN5 and 
CLN2, CLN3, CLN6 and CLN8 remain elusive 
In our experiments we showed that CLN5 interacts with many other NCL proteins; 
CLN2, CLN3, CLN6 and CLN8 (IV; figure 1, fig 9). The interactions of CLN5 with 
CLN2 and CLN3 have been previously published (Vesa et al. 2002a). The 
reproduction of these results here validates the earlier results. Only the mature 
lysosomal form of the CLN2 protein was pulled down with GST-CLN5, and not the 
precursor, indicating that unlike the interaction with PPT1, the interaction between 
CLN5 and CLN2 does not occur until within the lysosomes or late endosomes.  
Localiszation of all NCL interaction partners was studied in wt and Cln5 deficient 
mouse fibroblasts, but as in the case of PPT1, no changes in locations could be 
detected (IV; supplement 1). All binding partners were also overexpressed together 
with the transport deficient TD-CLN5 construct in HeLa cells. TD-CLN5 had only a 
minor effect on trafficking of CLN3 (IV; figure 2), and did not affect the 
localization of other interaction partners (IV; figure 3), supporting our pull down 
data, that suggests that the interaction with CLN2 occurs after the proteins have left 
the ER. CLN6 and CLN8 are both known to be ER resident, so it is likely to assume 
that the interactions between these proteins and CLN5 occur in the ER. As the 
trafficking of CLN3 was partially affected by the simultaneous expression of TD-
CLN5, it is possible that the two proteins interact already in the ER. Future studies 
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will help us to understand the consequences on the NCL pathology of the 
interactions in this CLN network. 
 
Figure 9. CLN5 interacts with CLN1, 
CLN2, CLN3, CLN6, CLN8 and with F1-
ATPase 
 
 
 
 
 
In summary, we have been able to show that CLN5 is connected to most other NCL 
proteins at the molecular level, suggesting a central role in the NCL interactome. 
Coimmunoprecipitation analysis would be a widely accepted method to verify the 
protein interactions but due to the lack of efficient antibodies the interactions were 
verified by GST-pulldown assays. GST-pulldown often requires overexpression of 
proteins to yield consistent results, as has been the case for most of our experiments. 
Furthermore, the cells have to be lysed and the proteins’ physiological environment 
is therefore disrupted, making it possible for proteins to interact with partners that 
they never normally come into contact with. We have however, been able to show 
that our claimed interactions are plausible with regard to the interaction site, as 
shown by immunofluorescence analyses.  
Other things to consider include possible protein misfolding, potentially leading to 
the exposure of hydrophobic surfaces and resulting in artificial interactions. This 
could be the case especially for CLN3, which is a transmembrane protein, known to 
be highly hydrophobic. On the other hand, CLN3 along with CLN2 have already 
previously been shown to interact with CLN5 by co-immunoprecipitation and in-
vitro binding assays (Vesa et al., 2002). Furthermore, the restricted spatial 
environment within a GST-pulldown assay, having both small internal cavities in the 
agarose beads and the capability of GST to dimerise, might give rise to restricted 
mobility and therefore enhance the apparent affinity of an interaction. Therefore, 
careful controlling of the experimental conditions is necessary and we have used a 
hydrophobic lysosomal transmembrane protein LAMP-1 as a negative control to 
exclude non-specific interactions. 
Yeast or mammalian two hybrid assay is an alternative method to GST-pulldown 
assay. The yeast two hybrid method was not utilized due to the fact that CLN5 does 
not have a homolog in the yeast and therefore the putative interactions may not be 
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present in the yeast environment. Mammalian two-hybrid assay is a relevant choice, 
but to our opinion it would not provide additional evidence as compared to GST 
pull-down technique since also this system utilizes overexpression of at least one 
interaction partner. In addition to the evidence of interactions obtained by the GST 
pull down assays, we feel that the identification of the common interaction partner 
for CLN1 and CLN5, the ATP-synthase, further provides a common funcitonal link 
to these two proteins and gives further support for the existence of the 
interactions.We have, also been able to confirm the alleged interaction between 
CLN5 and CLN1 on a functional level, which should reduce any concerns about the 
reliability of the interaction. 
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6 CONCLUSIONS AND FUTURE PROSPECTS 
In the course of this study CLN5 has been shown to localize to the lysosomes and 
interact with two other NCL proteins, CLN2 and CLN3 (Isosomppi et al., 2002; 
Vesa & Peltonen, 2002; Vesa et al., 2002a). CLN5 mutations have been found in 
patients outside northern Europe; in Columbia, Netherlands, Portugal and 
Newfoundland. Natural animal models with mutations in the CLN5 gene have also 
been discovered. vLINCLFin has been shown to exist in Border Collie dogs (Melville 
et al., 2005), Devon cattle (Houweling et al., 2006), and in Borderdale sheep 
(Frugier et al., 2008). 
Many other NCL mouse models have been generated and analyzed resulting in 
many common features for NCLs being discovered. The thalamocortical pathways 
have been shown to be affected in all studied mouse models for NCL. From these 
studies we now know that neurodegeneration initiating from the thalamus and 
subsequently moving to the cortex, combined with reactive gliosis is a common 
feature in all NCLs (reviewed by (Cooper et al., 2006)). We also know that selective 
loss of interneurons is evident in all NCLs, although this may be a general feature of 
lysosomal storage disorders as a whole. 
Due to the diligent efforts of Siintola and colleagues, we have recently been able to 
add two new NCL disease genes to this group. Mutations in the MFSD8 (Siintola et 
al., 2007) gene result in the variant late CLN7 disease, whereas mutations in 
Cathepsin D (Ctsd) gives rise to the congenital CLN10 (Siintola et al., 2006b). 
These two additions have enlarged the group of known NCL genes to eight, and 
existing family materials implicate that more NCL genes are yet to be identified.  
New interaction partners have been proposed for some of the NCL proteins. F1-
ATPase interacting with CLN1/PPT1 (Lyly et al., 2008) as well as Hook1 (Luiro et 
al., 2004), Calsenilin (Chang et al., 2007), Na+, K+ ATPase and Fodrin (Uusi-Rauva 
et al., 2008) interacting with CLN3, have connected these proteins with potential 
novel functions.  
We have focused our attention on the Cln5-/- mouse model, which has proven to be 
a valuable disease model for vLINCLFin. We started by analysing gene expression 
changes in the already symptomatic mouse, and were able to show that the mouse is 
affected by loss of myelin, inflammation and neurodegeneration related changes.  
We continued, thereafter, with characterization of the brain pathology of the Cln5-/- 
mouse. We revealed that the Cln5-/- mouse shares the same thalamocortical 
pathology with other NCL mouse models, but the order of events were opposite to 
those of all the other NCLs. In most NCLs it is the thalamic relay neurons that die 
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first whilst the neurons in the cortical target regions die later. In Cln5 deficient mice, 
the neurons die first in the cortex and only months later in the thalamus. We could 
similarly confirm that the same reactive glial responses are also present in our Cln5-
/- mice, as in all other NCL mice. We were, however, again able to point out some 
important differences. It has been shown that the localized reactive gliosis is present 
early in the disease progression, in the areas where neuron loss is subsequently about 
to occur. In the Cln5-/- mouse, it appears that the early onset reactive gliosis not 
only occurs much earlier than in the other models, it also occurs more prominently 
in the thalamus, which is not the brain area where the neurodegeneration initiates in 
Cln5-/- mice. In agreement with our previous gene expression analyses that revealed 
a downregulation of myelin associated genes, we could show that significant loss of 
myelin stained fibres is already evident at 1 month of age. 
We further performed gene expression studies on presymptomatic mice, as the early 
stages are most likely to pinpoint true dysregulated pathways. In these studies we 
included Cln1-/- mice into our analysis. Our hypothesis was that common changes 
in gene expression are likely in these two NCL mouse models, since the diseases are 
so alike. Indeed, we revealed a shared defected pathway in both mouse models. This 
pathway regulates the growth cone and cytoskeleton in neurons, and defects in it are 
known to affect neuronal migration.  We were additionally able to show that several 
genes of this pathway are most probably coregulated with CLN1, suggesting similar 
functionality between these coregulated genes. 
Based on our results for a shared pathway, and possibly similar functions, between 
Cln5 and Cln1, we wanted to find out if these two genes might interact. Since some 
reports indicated interactions between a few NCL-proteins, we additionally included 
other known NCL genes into our analysis. We were able to demonstrateby GST-
pulldown, interactions between CLN5 and CLN1, CLN2, CLN3, CLN6 and CLN8, 
connecting, for the first time, most of the known NCL genes to each other. 
Importantly, CLN5 seemed to represent a central molecule in this NCL interactome. 
The strongest interaction was found between CLN5 and CLN1. CLN1 had recently 
been shown to interact with the F1-ATPase, by surface plasmon resonance and 
GST-pulldown assays, so it was natural to investigate if CLN5 also interacted with 
it. Not surprisingly, we were able to show that CLN5 also interacts with the F1-
ATPase. We further demonstrated that the overexpressed PPT1 is able to facilitate 
the transport of the mutated CLN5 protein to its correct localization in the 
lysosomes. This is not the first time that lysosomal proteins have been shown to 
assist each other in their transport to lysosomes. Both the ClC7 chloride transporter 
(Lange et al., 2006) and the lysosomal membrane protein LIMP-2 (Reczek et al., 
2007) have been shown to assist the transport of their interaction parteners (OSTM1 
and β-glucocerebrosidase, respectively). In the case of LIMP-2, it was shown that it 
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is required for a M6-P independent targeting of the β-glucocerebrosidase to the 
lysosomes and as is the case with CLN5 and PPT1, overexpression of LIMP-2 is 
able to facilitate the correct transport of β-glucocerebrosidase from the ER to the 
lysosomes (Reczek et al., 2007). It has been thought that both PPT1 and CLN5 
would be targeted to the lysosomes via the M6-P dependent pathway (Sleat et al., 
2006; Sleat et al., 2007). Our data suggest that there may be alternative trafficking 
routes to the lysosomes for these proteins.  
This thesis has been able to shed light on the brain pathology of the Cln5-/- mouse 
and has led to the identification of several interaction partners for CLN5. 
We now know that the brain pathology begins early in the Cln5-/- mouse, much 
earlier than any visible symptoms. It starts with loss of myelin and reactive gliosis. It 
is hard to say if the loss of myelin results from oligodendrocytes dying or from a 
developmental defect in the assembly of myelin. Since 1 month is the earliest time 
point we have investigated, we can not rule out that the defect in myelin emerges 
even earlier than this. Nevertheless, the first signs of neuron loss in the cortex appear 
around the age of 4 months and this dying of cortical target neurons most likely 
affects the thalamic relay neurons which start dying a few months later.  
We have shown that these events are connected with disturbances of the 
cytoskeleton and the growth cone. Future studies will reveal, wether the cholesterol 
metabolism is altered in the Cln5-/- mouse, similarly to the Cln1-/- mouse, which 
also interacts with the F1-ATPase (Lyly et al., 2008). Cholesterol is a major lipid in 
the myelin sheath and it is possible that disturbances in the cholesterol metabolism 
would affect the assembly of the myelin sheath, leading to the loss of myelin we 
have observed in Cln5-/- mice. As all these different events can be connected to 
myelin disturbances, it would be of great interest to investigate if Cln5 harbours a 
specific role in oligodendrocytes. It might turn out that NCLs are diseases of 
neurodevelopment, rather than neurodegeneration.  
The function of the Cln5 protein still remains elusive. Future studies will reveal 
whether Cln5 harbours a function already in the ER, as the proposed interactions 
with Cln1, Cln6 and Cln8 appear to transpire already there. On the other hand, the 
interaction between Cln5 and the F1-ATPase connects Cln5 with the mitochondria 
and the plasma membrane. However, increasing evidence has shown us that 
vLINCLFin together with the rest of the NCLs may have to be considered in the 
future as other than purely lysosomal diseases. Regardless, the focus of the Cln5 
recearch, should switch from neurons to encompass all brain cells, including 
astrocytes and oligodendrocytes 
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